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ABSTRACT 
The Gram-negative bacterium Haemophilus ducreyi causes chancroid, a sexually 
transmitted infection characterized by persistent ulcers on genitals. The disease is prevalent in 
developing countries and facilitates transmission and acquisition of HIV.  
This thesis focuses on two bacterial virulence factors, lipooligosaccharide (HdLOS) and 
cytolethal distending toxin (HdCDT). The carbohydrate part of HdLOS is short and sialylated. 
HdCDT, an AB2 toxin composed of three protein subunits, induces DNA double strand breaks, 
cause cell cycle arrest and death of target cells. Protective immunity against H. ducreyi is not 
well understood. 
The general aim was to investigate the role of HdLOS and HdCDT in antibody responses, 
specifically to: 1) evaluate the function and viability of human monocyte-derived dendritic cells 
(DC), macrophages (MQ) and CD4
+
 T-cells after interaction with H. ducreyi bacteria, HdLOS 
and HdCDT, in vitro; 2) define immunogenic and adjuvant properties of HdLOS; 3) evaluate the 
impact of HdCDT on the serum antibody responses and 4) define a procedure for the generation 
of high antibody levels to HdCDT in the genital tract, using a mouse model. 
Bacteria and HdLOS stimulated an inflammatory cytokine response in the DCs and MQs, 
and activated cells induced CD4
+
 T-cells to proliferate and secrete INF-γ. HdCDT caused 
apoptosis of DCs, inhibited the secretion of cytokines and intoxication resulted in failure of 
CD4
+
 T-cells activation, in vitro. 
Purified HdLOS is an immunogenic T-cell independent antigen. The majority of HdLOS 
antibodies was specific for the inner core and did not neutralize endotoxin activity. HdLOS 
possessed adjuvant properties and significantly increased the antibody response to proteins 
tested. 
Active HdCDT is weakly immunogenic and induced low levels of specific antibodies. 
HdCDT did not down-regulate the antibody response to H. ducreyi antigens, despite the toxic 
activity on mouse immune cells, in vitro.  
High levels of specific HdCDT antibodies in serum and genital tissue, including 
neutralizing antibodies, were induced by parenteral immunization of mice with formaldehyde 
detoxified HdCDT alone or in combination with aluminum salts or lipid A based adjuvants. The 
HdCDT toxoid can be evaluated as useful component of a vaccine against H. ducreyi and other 
CDT producing bacteria.  
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ABBREVIATIONS 
AaCDT  Aggregatibacter actinomycetemcomitans cytolethal distending toxin 
APC   Antigen presenting cell 
CDT   Cytolethal distending toxin  
cfu   Colony forming unit 
DC   Dendritic cell 
DTH   Delayed type hypersensitivity  
FCS   Fetal calf serum 
GUD   Genital ulcer disease  
HdCDT  Haemophilus ducreyi cytolethal distending toxin 
HdLOS  Haemophilus ducreyi lipooligosaccharide 
HSP   Heat shock protein 
HSV   Herpes simplex virus 
LAL   Limulus amoebocyte lysate assay 
LOS   Lipooligosaccharide 
LPS   Lipopolysaccharide 
MQ   Macrophage 
MTT   Dimethylthiazol diphenyl tetrazolium bromide  
NLS   Nuclear localization factor 
NPP   p-nitrophenyl phosphatase  
OMP   Outer membrane protein 
PBMC   Peripheral blood mononuclear cells  
PCR   Polymerase chain reaction 
PI   Propidium iodide 
PMN   Polymorphonuclear leukocytes 
STI   Sexually transmitted infection 
TLR4  Toll-like receptor 4  
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INTRODUCTION 
 
The Gram-negative bacterium Haemophilus 
ducreyi is a strict human pathogen and the 
etiologic agent of the sexually transmitted 
infection (STI) chancroid (ulcer molle, soft 
chancre) (Fig 1). Chancroid is characterized 
by soft, painful, slow healing ulcers on the 
external genitalia which may be 
accompanied by regional lymphadenitis and 
bubo formation. The disease occurs 
worldwide with highest prevalence in the 
developing countries of Africa, Asia and 
Latin America. In these countries H. ducreyi 
is considered to be one of the major causes 
of genital ulcer disease and it facilitates the 
transmission and acquisition of HIV. 
 
 
Figure 1 Haemophilus ducreyi. The picture 
was kindly provided by Teresa Lagergård
1. HAEMOPHILUS DUCREYI BACTERIUM 
The bacterium Haemophilus ducreyi was first described in 1889 by Auguste Ducreyi [1]. It is a 
strictly human, fastidious Gram-negative coccobacillus that grows slowly with requirements of 
selective, enriched media and a microaerophilic environment for growth. For optimal growth a 
humidified and carbon dioxide enriched atmosphere at a temperature of 33° is applied. When 
grown on solid agar based media, bacterial colonies are characterized as small, non-mucoid, 
yellow-grey and semi-opaque. They are intercellular adhered and can be pushed intact across the 
agar surface. In liquid media the bacteria are arranged in chains and “schools of fish” [2-3]. 
 The classification of H. ducreyi among the Haemophilus species was based on the specific 
growth requirements, biochemical properties and antigenic relatedness to other species in the 
group [3], however rRNA analyses have shown that a more correct classification would be in 
the Actinobacillus cluster of the Pasteruellaceae [4-5]. The genome of H. ducreyi 35000HP (HP 
refers to human passaged) was completely sequenced in 2001 and it is composed of a single 
1.7x10
6
 bp chromosome that encodes for 1783 predicted genes. 
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2. CHANCROID  
2.1. EPIDEMIOLOGY OF CHANCROID  
Cases of chancroid occur worldwide with highest prevalence in the developing countries of 
Africa, Asia and Latin America. In these countries H. ducreyi was considered to be the major 
cause of genital ulcer disease for long time [6-7]. In a report from 1997, UNAIDS and the World 
Health Organization (WHO) estimated that the annual global incidence of chancroid was 6 
million cases [8]. However, the incidences of chancroid are declining and recent studies 
performed on ulcer specimens from genital ulcer disease (GUD) patients in Tanzania and South 
Africa report decreased detection of H. ducreyi (detected in 1.2 - 5% of ulcers), on the contrary 
the prevalence of Herpes simplex virus have increased (detected in 83 - 85% of ulcers) [9-10]. 
The disease is reported to be more prevalent in men than in women, with ratios ranging from 3:1 
in endemic areas to 25:1 in outbreak situations [3]. This difference in susceptibility between 
sexes is also seen in experimental infections in both humans and macaques [11-12]. One 
important cofactor in the spread of chancroid is prostitution and the prostitutes are considered as 
a reservoir of the disease in epidemic outbreak situations [13-14]. 
 Genital ulceration caused by H. ducreyi disrupts the mucosal integrity and thus provides a 
portal of entry for HIV explaining the strong correlation between genital ulcer diseases (GUD) 
and the acquisition and transmission of HIV [15-17]. Furthermore, the presence and activation 
of HIV- susceptible cells in the genital tract increased as a part of the cellular immune response 
to H. ducreyi. The cutaneouse infiltrate of CD4
+
 T-cells and macrophages that Spinola et al. 
reported of [18] are the primary targets for HIV and the increased CCR-5 receptor expression on 
the macrophages further increase the susceptibility of these cells to HIV [17]. H. ducreyi 
specific T-cell stimulating antigens might increase the viral replication in these cells [19]. The 
transmission of HIV is facilitated by viral shedding in ulcer exudates and from bleeding ulcers. 
Inappropriate handling of chancroid diagnostics and therapeutic procedure e.g. bubo aspiration, 
can also contribute to the spread of HIV. 
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2.2. CLINICAL MANIFESTATIONS, DIAGNOSIS AND TREATMENT 
Infection with H. ducreyi is initiated by the entry of bacteria through micro abrasions in the 
epidermis. After an incubation period of 4-7 days post infection the chancre begins as a tender 
erythematous papules that transform to eroded pustules in 24-48 h, after another 2-3 days the 
pustule ruptures and a painful shallow ulcer is formed [7, 13]. The ulcer is described as soft, 
having ragged undermined edges, no indurations and purulent exudates covering the base of the 
ulcer with little inflammation of the surrounding skin [20]. The type and the severity of the 
ulcers vary, in men they typically occur on the prepuce and frenulum and in women on the 
vulva, cervix and in the perianal area [7]. Unilateral inguinal lymphadenopathy is another 
typical characteristic of chancroid, it occurs in 50% of cases, and the affected lymph nodes may 
develop into buboes that rupture to form inguinal ulcers. However, these symptoms seem to be 
less common in women [3]. Without efficient treatment the infection is persistent and it can take 
several months before the infection is resolved and the ulcers are healed. 
 The “golden standard” for the diagnosis of chancroid has been based on physical 
examination, laboratory culture of ulcer and bubo pus specimens, and also by the exclusion of 
other genital ulcer diseases, such as; syphilis, herpes simplex virus and lymphogranuloma 
venereum [7]. In order to improve the diagnostic of chancroid several attempts were made to 
develop PCR-based diagnostic techniques [21-24] and the multiplex PCR (M-PCR) assay that 
simultaneously detects H. ducreyi, Treponema pallidum and herpes simplex virus (HSV) type 1 
and 2 from ulcer specimens is the most sensitive [25]. Still laboratory culture is the main 
diagnostic tool for detection of H. ducreyi, since this is the technique that is available in most 
clinical microbiology laboratories. 
 H. ducreyi have in the recent decades acquired antibiotic resistance by plasmid- and 
chromosomally- mediated mechanisms and nowadays is the treatment recommend for chancroid 
by WHO and the Centre for Disease Control; Azitromycin, Ceftriaxone, Ciprofloxacine or 
Erythromycin, in addition aspiration of buboes is recommended to avoid complications of 
spontaneous rupture [7].  
2.3. HISTOPATHOLOGICAL FEATURES  
Biopsies from chancroid proven ulcers have been used for the study of the histological features 
of natural occurring chancroid. The ulcers have been described as three discrete zones; the 
superficial zone, the edge and the base of the ulcer, consists of necrotic tissue, fibrin, neutrophils 
and many Gram-negative coccobacilli; the middle zone, dominated by endothelial cells, shows 
oedema and newly formed blood vessels perpendicular to the surface of the ulcer; the deep layer 
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manifesting a dense infiltrate of neutrophils, plasma cells, T-lymphocytes and leukocytes with 
fibroblastic proliferation [20, 26-28]. Biopsies from the pustule stage in experimental human 
infection showed similar histological features as the ones taken from ulcers in natural occurring 
infection [18, 29]. In this stage of the infection, the majority of the infiltrated cells was reported 
to be; T-cells (60-80% were CD4
+
 and 20-40% were CD8
+
) and mononuclear cells (mainly 
macrophages), even though a smaller portion of the infiltrated cells were B-cells and NK cells 
there were no plasma cells detected at this early stage of infection. 
3. HAEMOPHILUS DUCREYI MODELS FOR THE STUDY OF PATHOGENESIS  
Even though H. ducreyi is solely a human pathogen researchers have tried to establish models to 
be able to study the virulence and pathogenesis of the bacteria and both in vitro and in vivo 
models have been developed [12, 30-37]. Established cell lines as well as cell cultures of either 
human or animal origin have been used for the in vitro studies. The models mainly used for  
in vivo studies are; 
1) Rabbits were for many years used in the evaluation of the virulence of H. ducreyi strains, by 
the use of this model, a strain was defined as virulent when intradermal inoculation of 
approximately 10
8
 cfu bacteria generated a typical lesion, characterized by necrosis and eschar 
formation [30-31]. If no cutaneous lesion formed the strain was defined as avirulent. In 1991, 
Purcell et al. reported of a temperature dependency of the rabbit model [32]. Inoculation of 10
5
 
cfu H. ducreyi bacteria, unable to produce lesions in rabbit skin when the animals were housed 
at normal temperature, produced lesions when the rabbits were housed at a reduced temperature 
(15-17°C). Some histopathologic features are shared such as the presence of dermal perivascular 
lymphocytic and plasma cell infiltrates, but the main disadvantage of the rabbit model is that the 
lesion development do not resemble the human chancroid [32]. 
 Wising et al. used the temperature dependent rabbit model for the investigation of toxicity 
and immunogenicity of purified H. ducreyi cytolethal distending toxin (HdCDT) and they also 
showed that HdCDT aggravated the dermal lesions caused by H. ducreyi [38-39]. 
2) The primate model developed by Totten et al. consists of adult pigtailed macaques  
(Macaca nemestrina) of both sexes inoculated with 10
7
-10
8
 cfu of H. ducreyi [12]. The males 
were inoculated on the foreskin and the females on the vaginal labia, all of the male macaques 
developed ulcers that closely resembled those of natural occurring chancroid, while none of the 
female macaques developed ulcers. Both the rabbit and the macaque model were reported to be 
dependent on the viability of the inoculated bacteria for formation of ulcers. 
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3) Mice were used in an attempt to develop a model that presented ulcers that more resembled 
natural occurring chancroid [33]. After intradermal or subcutaneous inoculation of 10
7
 cfu  
H. ducreyi the animals developed both pustular nodules and severe ulceration that resembled a 
human infection. Further evaluation of the model showed that the same type of ulcers was 
formed when mice were inoculated with either heat killed H. ducreyi or 10
8
 cfu of viable or heat 
killed Neisseria gonorrhoeae and also by inoculation of purified lipooligosaccharide (LOS) 
from any of the bacteria [34]. According to these data ulcers were not produced specifically by 
H. ducreyi. 
 When Campagnari et al. evaluated the role of LOS in experimental dermal lesions caused 
by H. ducreyi in mice and rabbits they concluded that H. ducreyi LOS might play an important 
role in the pathogenesis of chancroid and that the rabbit model could be useful for the study of 
H. ducreyi LOS at a cellular level [40]. Furthermore, Lagergård evaluated the capacity of  
H. ducreyi strains that were cytotoxin positive or negative, bacterial sonicates and purified LOS 
from the same strains for the ability to induce dermonecrotic lesions and ulcers in mice and 
rabbits [35]. The results showed that the same type of lesions was caused by the different 
bacterial strains, bacterial sonicate and LOS. Furthermore ulcer formation caused by bacterial 
sonicates and LOS was found to correlate with the endotoxic activity in the preparation, 
consequently Lagergård concluded that LOS could play a role in the ulceration caused by  
H. ducreyi in animals.  
4) In the swine model juvenile pigs are injected with approximately 4x10
3
 – 4x104 cfu bacteria 
on the dorsal side of the ear with a Multi-Test Applicator (allergy testing device) [36-37]. The 
skin of the juvenile pig closely resembles the human skin both structurally and physiologically 
and the lesions that are developed in pigs have histological resemblance to natural human 
chancroid. A great advantage of this model is the possibility of multiple injection sites, which 
provides a valuable tool for the evaluation of different as well as genetically modified strains in 
the same animal. Furthermore, pigs have been reported to mount a partially protective humoral 
immune response to H. ducreyi, which might suggest this model as valuable for the evaluation 
of vaccine candidates [37]. 
5) The human model for experimental infection with H. ducreyi was developed by Spinola et al. 
in order to study the pathogenesis of H. ducreyi and the host inflammatory response to the 
organism [41]. The model is standardized and approximately 10
1
 to 10
3
 cfu of bacteria are 
delivered to the epidermis and dermis of the upper arm using a allergy testing device [42]. After 
inoculation, papules are formed within 24 hours that either evolve into pustules after another 2-5 
days or resolve spontaneously. For safety reason three clinical end points are set up; 1) disease 
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at all sites resolved, 2) development of a pustule that is either painful or > 4 mm in diameter, or 
3) 14 days has passed after inoculation. All volunteers are treated with one oral dose of 
ciprofloxacine when they reach either of the end points. Since infection is not allowed to 
proceed more than 14 days, this model only represents the early stages in chancroid. For the use 
of this model, the difference between the structure of the skin on the arm and on the external 
genitalia is important to keep in mind. 
 This model is extensively used in the search for putative virulence factors, occasionally in 
combination with the swine model. Many of the performed virulence studies are isogenic 
mutant-parent comparison trails and the mutated bacteria is classified as; 1) attenuated when it is 
unable to cause pustule formation even at doses 10-fold greater than the parent dose that resulted 
in pustule formation, 2) partially attenuated when the mutant is able to cause pustule formation 
at doses 2- or 3-fold greater than the parent dose that resulted in pustule formation, or 3) virulent 
when the mutant is able to cause pustule formation at a dose equivalent to the parent dose that 
resulted in pustule formation [43]. 
Despite all attempts there is still no usable model for the study of chronic H. ducreyi 
infection, which can be used for the evaluation of H. ducreyi cytotoxic activity on the 
development and persistence of ulcers. Neither is there any suitable model for the study of 
protection against infection.  
4. HAEMOPHILUS DUCREYI PATHOGENESIS AND VIRULENCE FACTORS  
H. ducreyi has developed several mechanisms for the initiation and establishment of infection. 
In the initial stage of infection bacteria are found co-localized with collagen, fibrin, PMNs and 
MQs, although bacteria are surrounded by phagocytes they remain extracellular throughout 
experimental human infection and resist killing by the phagocytes [44]. Furthermore, several 
reports have suggested the ability of H. ducreyi to evade complement mediated serum killing 
[45-47]. The cytotoxic virulence factors haemolysin, cytolethal distending toxin (CDT) and LOS 
are of great importance as they probably are involved in the establishment of persistent ulcers 
and the evasion of host immune responses[48]. LOS and CDT will be described in detail in a 
later section of this thesis (page 19-29).  
Some of the virulence factors reported to be involved in the pathogenesis of H. ducreyi is 
listed in Table1. 
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Table 1. Haemophilus ducreyi virulence factors 
VIRULENCE FACTORS INVOLVED IN ADHERENCE       REF 
FgbA Fibrinogen binder [49] 
FtpA  Fine tangled pili [50] 
GroEL Heat shock protein [51] 
NcaA Necessary for collagen adherence [52] 
TadA Tight adherence protein [53] 
VIRULENCE FACTORS INVOLVED IN THE RESISTANCE TO PHAGOCYTOSIS 
LspA1,  
LspA2 
Large supernatant proteins [54] 
SOD Superoxide dismutase  [55] 
VIRULENCE FACTORS INVOLVED IN SERUM RESISTANCE 
DltA Ducreyi lectin A  [47] 
DsrA  Ducreyi serum resistance A  [45] 
MOMP Major outer membrane protein [56] 
LOS Lipooligosaccharide [35] 
VIRULENCE FACTORS INVOLVED IN CYTOTOXICITY 
LOS Lipooligosaccharide [35] 
hhdA; hhdB Genes encoding haemolysin [48] 
HdCDT H. ducreyi cytolethal distending toxin [57] 
VIRULENCE FACTORS INVOLVED IN DISEASE PROGRESSION  
HgbA Hemoglobin-binding OMP [58] 
PAL Peptidoglucan associated lipoprotein [59] 
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5. HOST RESPONSE TO HAEMOPHILUS DUCREYI  
The human disease chancroid is caused by a natural H. ducreyi infection. Re-infection occurs 
frequently and the duration of the disease is often several months as a consequence of 
improperly treatment. Though, it must be mentioned that spontaneous resolution of the disease 
occasionally occurs. The course of disease is affected by the type of immune response that is 
generated during natural infection. Although chancroid is a sexually transmitted infection, not 
much is known about the immune response that is generated locally in the genital tract.  
 Infection is initiated when H. ducreyi enters the physical barrier that an intact skin 
constitute, this can occur via superficial abrasions in the genital skin or mucosa caused by sexual 
intercourse [3]. The first cells recruited to the site of infection are important in the innate 
immune response. In both natural chancroid and in the experimental human model there the 
lesions infiltrated with both PMNs and macrophages and the primary function of these cells are 
to phagocytose microbes, kill and eliminate them [60]. H. ducreyi is reported to be relatively 
resistant to phagocytic killing, in vitro [61-62]. In the human model, bacteria are reported to be 
closely related to, but not internalized by macrophages or neutrophils [44]. Furthermore,  
H. ducreyi were only able to produce lesions in granulocyte- and monocyte depleted mice, while 
no lesions were developed in normal or severe combined immune deficiency (SCID) mice [61]. 
Thus, indicating the importance of phagocytes in the defense against the bacteria in the mice 
model. 
 The activation of macrophages, natural killer cells (NK), antigen-specific CD8
+
 T-cells 
and the release of cytokines/chemokines in response to antigens are important factors of the cell 
mediated immunity. In the experimental human model, CD4
+
 CD45RO
+
 T-cells and 
macrophages were reported to be the major cellular infiltrate, but CD8
+
 T-cells and few B-cells 
were present in dermis. Furthermore, the expression of MHC class II (HLA-DR) in 
keratinocytes, dendritic cells and mononuclear cells was increased in pustules [18, 29]. These 
results suggest antigen presentation and cell mediated immune response in the early stages of 
infection. 
 T-cell mediated immune responses can be divided into two types, Th1 and Th2. The prior 
is characterized by the secretion of (interferon) IFN-γ, TNF-α, and IL-2, and by activation of 
macrophages, while Th2 type response is characterized by the lack of IFN-γ and the presence of 
IL-4, IL-5, IL-13 and the production of antibodies [63]. The type of cytokines that are expressed 
in natural occurring chancroid is not clear. Palmer et al. reported of the presence of IFN-γ in all 
lesions, whereas the expression of IL-2, IL-4, and IL-5 varied [29]. Humans are reported to 
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mount what appears to be a delayed type hypersensitivity (DTH) reaction in response to 
chancroid and experimental H. ducreyi infection [27, 29, 41, 64]. DTH reaction is a cell 
mediated response of the Th1 type, in which activation of macrophages and inflammation may 
cause tissue injury [65]. This type of response does not confer protection against subsequent re-
infection, neither is it effective at clearing chancroid infections, as lesions can persist for weeks 
or months, and ulcer resolution is often incomplete in the absence of antibiotic therapy [66]. 
 The majority of H. ducreyi bacteria present in chancroid lesions are reported to be 
extracellular [44]. The humoral immune response is of great importance in the defense against 
extracellular bacteria and their toxins. There are reports of serum antibodies specific to the heat 
shock protein (GroEL), LOS and HdCDT in chancroid patients [67-69]. The prevalence of 
antibodies to HdCDT and the individual components was significantly higher in both chancroid 
and periodontitis patients as compared with Tanzanian blood donors [70]. Furthermore, 
antibodies to H. ducreyi antigens are not detected in sera from experimentally infected humans 
[18]. Even though both cell mediated and humoral immune responses are induced by natural  
H. ducreyi infection the patients are not protected against subsequent infection.  
 Humphreys et al. used microarrays to profile the gene expression in infected and wounded 
skin of experimental H. ducreyi infected humans, and reported that DCs from volunteers that 
continuously resolved the experimental infection responded differently to H. ducreyi [71]. They 
suggested the non resolvers to promote a dysregulated T-cell response which contributed to the 
phagocytic failure, while the DC s from volunteers that resolved the infection probably 
promoted a Th1 response that facilitated bacterial clearance. 
In the temperature-dependent rabbit model, the animals were shown to be protected against 
experimental challenge f a single experimental infection with H. ducreyi, immunization with 
cell wall components, a pilus preparation or purified hemolysin [72-75]. Pigs were not protected 
from subsequent infection by a single exposure to H. ducreyi, but after three inoculations pigs 
developed a modest, but significant level of protection against bacteria [36]. Protection was 
defined as a reduction in disease severity as indicated by reduced recovery of viable bacteria. In 
addition, transfer of H. ducreyi immune serum protected naïve juvenile pigs against challenge 
with bacteria, thereby proving pigs to mount an effective humoral immune response to  
H. ducreyi after multiple exposure to the organism [37].  
6. LPS AND HAEMOPHILUS DUCREYI LIPOOLIGOSACCHARIDE  
Lipopolysaccharide (LPS), a major component in the outer membrane of the Gram-negative 
bacteria, is considered to be an important virulence factor and is essential for the viability of 
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bacteria. LPS and LOS are reported to be involved in the pathogenesis of disease by activation 
of human immune cells and subsequent production of pro-inflammatory cytokines and 
chemokines [76-77]. 
 LPS can be described as a complex glycolipid which can be divided structurally into three 
parts; 1) lipid A, the hydrophobic domain that is attached in the outer membrane and responsible 
for the biological activity, 2) the core, a non repeating oligosaccharide covalently attached to 
lipid A, which can be further divided into the inner core consisting of heptose and Kdo  
(3-deoxy-D-manno-2-octulosonic acid), and the outer core with structural diversity and an 
attachment site for the O-antigen, and 3) the O-antigenic side chain, a distal repetitive 
polysaccharide [78].  
 Lipid A is the moiety of LPS reported to be responsible for the biological activities 
referred to as “endotoxic” effects [76, 79-80]. An endotoxic effect is initiated by the binding of 
free LPS to LPS-binding protein and CD14, and thereafter recognition of complex by Toll-like 
receptor 4 (TLR4), subsequently leading to activation of intracellular signaling pathways 
resulting in the release of pro-inflammatory mediators (reviewed in [81]). The outcome of 
endotoxic activity varies, some important effects caused by endotoxin are lethal toxicity, 
pyrogenicity, induction of leukocytosis, platelets aggregation, complement activation, mitogenic 
activity of B-cells, adjuvant and immunomodulating activity, etc. [80]. Intradermal injection of 
lipid A in mice resulted in induction of vascular permeability followed by hemorrhagic necrosis 
in the dermis [82]. 
 The LPS produced by H. ducreyi lacks the repeating O-antigens, thus an LOS, and 
contains a variable and branching core oligosaccharide [83-84].  
6.1. STRUCTURE OF HDLOS 
The structure of H. ducreyi LOS (HdLOS) produced by different bacterial strains have been 
characterized in several studies [83, 85-91]. The carbohydrate chain in the LOS produced by 
different H. ducreyi strains were reported to vary in length from 5 to 11 monosaccharides, about 
10% to 50% of the LOS molecules were sialylated and the majority of H. ducreyi strains 
expressed the nonasaccharide form of HdLOS [88]. HdLOS contains a major glycoform with 
immunochemical identity to paragloboside, a glycoshingolipid precursor of human blood 
antigens and molecular mimicry of host structures by HdLOS is a suggested mechanism for  
H. ducreyi to evade the natural host defense [86]. In addition, the terminal portion of the HdLOS 
is reported to be involved in the adherence to and the invasion of human keratinocytes by  
H. ducreyi [92]. 
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 The structure of HdLOS produced by different H. ducreyi strains have been determined, in 
1995 and 1997, the structure of LOS from H. ducreyi strain 4438 and 7470 were published by 
Ahmed et al. (Fig 2) [85, 88-89].  
 
A) 
 
-NeuAc-(23)--Gal-(14)--GlcNAc-(13)--Gal-(14)--Hep-(16)--Glc--(14)--Hep-(15)--KDO4P-Lipid A 
                                                                                                                                                                       
                                                                                                                      -Hep-(12)--Hep-(13) 
B) 
 
                                                                          -NeuAc-(23)--Gal-(14)--Glc--(14)--Hep-(15)--KDO4P-Lipid A 
                                                                                                                                                                 
                                                                                                                -Hep-(12)--Hep-(13) 
 
Figure 2. Structure of H. ducreyi LOS purified from (A) strain 7470 and (B) strain 4438; strain 
4438 misses internal trisaccharide (in bold). 
 
 Post and Gibson defined two classes of H. ducreyi strains, based on the protein profiles 
and LOS structures from various strains, which generally are well conserved, class 1 strains 
predominantly express a nonasaccharide, whereas class 2 strains synthesise a pentasaccharide, 
the latter terminating in N-acetylglucosamine and does not act as acceptor for sialic acid [91]. 
6.2. HDLOS ROLE IN PATHOGENESIS AND IMMUNITY 
The literature describes the biological activity of endotoxin well and as mentioned before LOS 
have been reported to be involved in the pathogenesis of disease by the activation of human 
immune cells and the subsequent production of pro-inflammatory cytokines and chemokines 
[76, 78, 80]. Nevertheless, the role of HdLOS in the pathogenesis of chancroid is still not well 
evaluated.  
 Intradermal injection of LOS was reported to cause inflammation and tissue destruction in 
rabbits and mice [34-35, 40]. The expression of glycoforms with sugar moieties that extend 
beyond the heptose trisaccharide core was not required for the formation of pustules by  
H. ducreyi in human subjects subcutaneously injected with different H. ducreyi LOS mutants 
[93]. Nevertheless the role of HdLOS in the pathogenesis of chancroid is still not well evaluated. 
 HdLOS specific antibodies were detected in sera from chancroid patients, as well as in 
sera form blood donors [94-95]. Alfa et al. described the differences between the levels of serum 
anti-HdLOS antibodies in sera from endemic chancroid areas in Uganda and Kenya, and Canada 
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where chancroid is not endemic. They reported HdLOS to stimulate a specific immune response 
to H. ducreyi and postulated that ELISA could be useful as serological tool [94]. In an outbreak 
of chancroid in the United States, LOS EIA was used for the detection of serum anti- HdLOS 
IgG antibodies and the result of the IgG LOS EIA performed on initial sera from GUD patients 
was compared with multiplex (M)-PCR result of genital lesion specimens [95]. The LOS EIA 
was found to have a low sensitivity, only 48% of the patients that were M-PCR positive for 
chancroid were positive in the LOS EIA. In addition, no increase in seropositivity was detected 
in follow up sera. The authors concluded that the LOS EIA might be a useful epidemiologic tool 
in areas where PCR cannot be applied and that the use of serological assays for diagnosis of 
chancroid was not applicable, based on the fact that it takes several weeks of ulcerative 
symptoms before antibodies are developed [95]. 
 Odumeru et al. suggest the different composition of H. ducreyi LOS to be involved in the 
susceptibility to complement-mediated serum bactericidal activity [96]. Later, Frisk et al. 
reported antibodies specific to LOS to be incapable of enhancing the killing of bacteria [97]. 
However, the specificity of anti-HdLOS antibodies as well as their contribution to immunity 
needs further evaluation.  
7. HAEMOPHILUS DUCREYI CYTOLETHAL DISTENDING TOXIN AND THE CDTS 
H. ducreyi produces a cytolethal distending toxin (HdCDT), first described in 1992 by  
Purvén and Lagergård [57]. The HdCDT belongs to the CDT family of recently discovered 
bacterial protein toxins. 
 The first report of this novel type of toxin activity was presented in 1987 by Johnson and 
Lior [98]. They observed that culture supernatant from pathogenic strains of Escerichia coli 
caused distension of cells cultured in vitro, that after 3-5 days resulted in cell death. Later the 
authors report that both Shigella spp and Campylobacter spp possessed the same type of toxic 
activity and named the putative toxin, “cytolethal distending toxin” [99-100]. In 1994, the toxin 
was sequenced from a pathogenic E. coli strain for the first time and it was found that the CDT 
was encoded by three chromosomally linked genes [101]. 
 Throughout the years, several CDT producing Gram-negative bacteria other than  
H. ducreyi have been identified and sequenced through the years, e.g. E. coli, Shigella spp., 
Campylobacter spp., A. actinomycetemcomitans, several Helicobacter spp., Salmonella 
paratyphi (only cdtb) and Salmonella enterica serovar Thypi (only cdtb) [100, 102-113]. So far, 
no Gram-positive bacteria have been found to produce CDT. The CDT-nomenclature proposed 
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by Cortes-Bratti et al. that specifies the different CDTs by indicating the producing bacterium 
before CDT, e.g. HdCDT for H. ducreyi CDT, will be employed in this thesis[114].  
7.1. GENETICS OF HDCDT 
The HdCDT similarly to other CDT is encoded by closely located nearly, or slightly overlapping 
open reading frames (ORFs), cdtA, cdtB, and cdtC, with three known promoters located 
upstream from the first ORF, with a rho-independent transcription terminator located 3‟ from 
the third ORF [115] Transcript analyses of the H. ducreyi cdt gene cluster indicated the three 
genes to be transcribed in a single transcript [115]. The cdt gene cluster is chromosomally 
located in all species, except for one E. coli strain where it is located on a Vir plasmid [104]. 
Furthermore is it possible that the cdt genes have disseminated among H. ducreyi and other 
Gram-negative bacteria, since it is known that DNA close to the cdt genes have been acquired 
by horizontal transfer [104, 107, 115]. Nucleotide sequence analysis of H. ducreyi chromosomal 
DNA both upstream and downstream from the cdt gene cluster reveal the presence of ORFs with 
homology to proteins involved in transposition [115]. Moreover, sequences upstream the cdt 
gene cluster of A. actinomycetemcomitans were found to be related to a bacteriophage 
attachment site [107]. Likewise, sequences near the genes encoding EcCDT-III on the Vir 
plasmid were found to be phage and insertion-sequence remnants [104]. In the genomes of  
S. enterica serovar Thypi and S. paratyphi have only sequences that encodes for the cdtB gene 
been found and no homologues are detected that encode for cdtA and cdtC [112] However have 
S. Typhi been found to encode for two genes, pltA and pltB, in the same pathogenicity islet as 
cdtB, with homology to components of the pertussis toxin, including its ADP-ribosyl transferase 
subunit [116].  
7.2. H. DUCREYI CDT SUBUNITS AND HOLOTOXIN 
The cdtA, cdtB and cdtC genes in H. ducreyi were found to encode for proteins with predicted 
molecular weights of 24.7, 31.5, and 20.6 kDa, respectively, the molecular weight of the mature 
form of these proteins were found to be 23, 29, and 19 kDa, respectively [122, 125]. The amino 
acid identity for CDTs from different species varies from 19 to 97% [117]. When the HdCDT 
subunits were compared with other CDTs, the CdtB was found to be the most conserved one of 
the proteins and displayed higher homology (47-50%), than CdtA (25-33%) and CdtC  
(21-25%), [117]. The highest homology were reported between the HdCDT and  
A. Actinomycetemcomitans CDT (AaCDT), ranging from 92 to 97% [107, 117].  
 In 2002, the three HdCDT subunits as well as the HdCDT holotoxin were successfully 
purified by Wising et al. [38]. 
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 The CdtB produced by E. coli and C. jejuni were described to possess a 
deoxyribonuclease I (DNase I)-like enzymatic activity [118-119]. A position-specific homology 
between the CdtB subunit from EcCDT-II and mammalian DNase I was reported by Elwell and 
Dreyfus [118]. The homology pattern was found at specific residues involved in enzyme 
catalysis (Glu86, His154, Asp229, His261), DNA binding (Arg123, Asn194), and metal ion 
binding (Glu62, Asp192, Asp260).Furthermore, the CdtB contained a pentapeptide sequence  
(aa 259-263: Ser-Asp-His-Tyr-Pro) found in all DNase I enzymes. The DNase activity, as well 
as the cytotoxicity, was abolished by point mutations of conserved residues and the catalytic 
DNase activity appeared to be essential for the cytotoxic activity of CDT [118]. 
 Frisk et al. constructed recombinant plasmids that allowed the expression of each HdCDT 
gene individually or in different combination in E. coli and Vibrio cholera and found that it was 
it the CdtB component that possessed the DNase activity [120]. Moreover, have Shenker et al. 
reported of a phosphatidylinositol (PI)-3,4,5-triphosphate phosphatase activity of AaCdtB, when 
conserved amino acids critical to catalysis in the phosphatidylinositol 5-phosphatase family of 
enzymes were mutated, the activity was abolished [121]. In addition, these mutations caused a 
decrease in the ability to induce G2 arrest. 
 From the beginning the roles of HdCdtA and HdCdtC in the generation of cytotoxicity 
were not defined. However, several studies have demonstrated that all three subunits must be 
expressed for the generation of cytotoxicity by H. ducreyi and other CDT producing bacteria 
[102, 106, 115, 120].These findings were confirmed when crystal structure of HdCDT was 
determined in 2004 by Nesic et al.[122]. The crystal structure of the holotoxin revealed that 
HdCDT is a tripartite complex consisting of an enzyme of the DNase-I family, CdtB, bound to 
two lectin-type structures, homologous to the B-chain repeats of the plant toxin ricin, CdtA and 
CdtC. The subunits form a complex with three independent molecular interfaces characterized 
by globular and non-globular interactions (Fig 3) [122]. The authors suggested, based on the 
close interplay of CdtA and CdtC that they probably work together for a related function, which 
is likely to be the receptor binding of the complex. This knowledge supports the hypothesis that 
HdCDT is an AB2 toxin, with CdtA-CdtC as the binding subunit (B2) and CdtB as the active 
subunit (A). 
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Figure 3. Crystal structure of HdCDT, 
shown as a ribbon cartoon tracing the three 
polypeptide chains. N, amino terminus; C, 
carboxy terminus.  
Adapted by permission from Macmillan 
Publishers Ltd: [Nature] [122], copyright 
(2004). 
 
 
 
 
 
 
 
7.3. CDT ACTIVITY IN VITRO 
In 1992, the effects of a cytotoxin produced by H. ducreyi were reported by Purvén and 
Lagergård [57]. Epithelial cells were observed to be enlarged, elongated and rounded as a 
response to H. ducreyi cytotoxin intoxication. The human epithelial cell lines HEp-2, HeLa, and 
A549 were reported to be more sensitive to the cytotoxic activity than human and animal 
fibroblasts, even though morphological changes were observed in these cells [57].  
 The most apparent morphological effect of CDT is the cell distension which leads to a 
three-five fold increase of the cell size. Together with cellular distension the actin cytoskeleton 
is strongly promoted; this effect can be detected as the appearance of actin stress fibers  
[123-124]. After continued incubation with cytotoxin, cells round up, show membrane blebbing 
in some cases, and then deteriorate completely (Fig 4). In contrast to fibroblasts and epithelial 
cells, T-cells, B-cells and dendritic cells do not distend, but rather become apoptotic and 
fragmented after CDT treatment [125-127]. Nowadays almost all known CDT are reported to 
cause this type of distension on cultured cells, in vitro [112]. 
 26 
 
A 
 
B 
 
Figure 4. Morphological changes caused by HdCDT intoxication of human HeLa cells. 
A) Cells incubated with PBS. B) Cells treated with HdCDT (10 ng/ml) for 48h. 
Above pictures were kindly provided by Teresa Lagergård.  
 
 The initial step in CDT intoxication is the binding of the toxin to the cell, and similar to 
other intracellular toxin the internalization is an important step, still unfortunately no receptor 
has been identified for HdCDT. Thus, for AaCDT is the ganglioside GM3 reported to be a 
possible CDT receptor [115]. The binding of AaCDT to its cell surface receptor is suggested to 
be mediated predominantly by the CdtA subunit [128]. Expression of recombinant HdCdtA and 
HdCdtC in E. coli resulted in the formation of a non-covalent CdtA-CdtC complex, capable of 
binding to HeLa cells, addition of purified CdtB caused cell death within 72 h [129]. HeLa cells 
pretreated with the CdtA-CdtC complex were prevented from cell death by addition of  
H. ducreyi culture supernatant containing HdCDT holotoxin, which completely killed untreated 
cells. Guerra et al. reported the binding of HdCDT to the plasma membrane of sensitive cells to 
be dependent on cholesterol [130]. This was confirmed for AaCDT when Boesze-Battaglia et al. 
reported that cholesterol-rich cytoplasmic membrane lipid rafts were involved in the delivery of 
AaCdtB into target cells [131]. By depletion, inhibition and genetically manipulation studies 
HdCDT were shown to enter HEp-2/HeLa cells by endocytosis via clathrin-coated pits [132]. 
The cellular intoxication was inhibited if the fusion of early endosomes with downstream 
compartments was blocked or if agents that disrupted the Golgi complex were used. The authors 
concluded that the toxin, after uptake via clathrin-coated pits, required transport in vesicles at 
least to the Golgi apparatus before it could be activeated [132]. Another study confirmed these 
results by reporting that the toxin were internalized via the Golgi complex and thereafter 
 27 
retrogradely transported to the endoplasmic reticulum (ER) [130]. In an assay using transient 
expression of a series of truncated AaCdtB-green fluorescent protein (GFP), a 76-amino acid 
sequence (residues 48-124) was reported to constitute an atypical nuclear localization signal 
(NLS) [133]. Microinjected His-tagged AaCdtB-GFP entered the nucleus within 3-4 hours. It 
was also demonstrated that a holotoxin containing an 11-amino acid truncation in the identified 
NLS of AaCdtB were unable to intoxicate the cells. This observation suggested that the 
identified NLS may be functional for nuclear localization of the toxin also when cells are 
naturally intoxicated [133]. In 2004, two NLS sequences, designated NLS1 and NLS2 were 
identified in the carboxyterminal region of EcCdtB-II [134]. Most recently it was found that 
HdCdtB was heat stable and resisted degradation, it was suggested that the toxin subunit did not 
unfold before exiting the ER and might move directly from the ER lumen to the nucleoplasm 
[135]. This though HdCdtB does not contain any known conventional NLS.  
 The outcome of HdCDT intoxication varies depending on the cell type affected. Several 
cell types are reported to be sensitive to the toxin e.g. HEp-2, HeLa, Jurkat T-cells, THP-1, 
HaCat, Vero and Don Fibroblasts [115, 124, 136]. Intoxication of HeLa cells with HdCDT 
caused DNA double strand breaks, similar to ionizing radiation (IR) [137]. The toxin is believed 
to act as a genotoxin by causing DNA lesions, and consequently induce cellular responses that 
result in cell cycle arrest and cell death through apoptosis/necrosis. HdCDT intoxication of; 
epithelial cells and normal keratinocytes causes cell cycle arrest exclusively in G2, normal 
fibroblasts show cell cycle arrest in both G1 and G2 phase of the cell cycle while B-cells are 
reported to undergo apoptosis [126]. Moreover, HdCDT is reported to inhibit proliferation of 
normal human T-cells and B-cells, and to affect normal human endothelial cells (HUVEC)  
[138-139]. The two rabbit cell lines; SIRC (fibroblast-like cells from cornea) and RK13 
(epithelial-like cells from kidney) were affected both in the metabolic activity and arrested in the 
G2 phase of the cell cycle by HdCDT intoxication [38]. Wising et al. described that HdCDT 
induce different levels of apoptosis and necrosis in a dose- and time dependent manner in 
different types of cells. Early and late apoptosis were induced in more than 90% of T-cells and 
monocytes, but only in 26-32% of the epithelial cells, kerationcytes and fibroblasts [140]. The 
authors concluded that HdCDT effectively eliminate the cells that are involved in immune 
responses by inducing apoptosis. Additionally, cells that are of importance in the healing of 
chancroid ulcers were driven into apoptosis or necrosis.  
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7.4. CDT ACTIVITY IN VIVO 
The knowledge of how HdCDT contribute to the pathogenesis of H. ducreyi in natural hosts or 
in experimental animal models is relatively limited. However since there is a high prevalence of 
cdt in H. ducreyi, C. jejuni, and A. actinomycetemcomitans CDT might be an important 
virulence factor in infections caused by these pathogens. There are, however, only few studies 
reported on the actual importance of CDT in vivo. 
 The in vivo activities of CDT in H. ducreyi infection were studied using isogenic mutants 
to the different CDT components. An isogenic H. ducreyi cdtC mutant was reported to be as 
virulent as the wild-type strain in the temperature-dependent rabbit model of chancroid, despite 
the fact that it was not cytotoxic to HeLa cells and keratinocytes [141]. In addition isogenic  
H. ducreyi cdtA and cdtB mutants were presented to be as virulent as the wild-type strain with 
regard to lesion production in the same rabbit model [142]. Furthermore, the expression of CDT 
was not required for pustule formation by H. ducreyi in the experimental human model [143]. 
Wising et al. used the temperature dependent rabbit model and reported of HdCDT induced 
inflammation in rabbit skin when injected alone and HdCDT contributed to the local 
aggravation and retardation of the healing of skin when it was injected together with a non-toxin 
producing strain of H. ducreyi [39]. 
 For C. jejuni the CDT was reported to be essential for a persistent infection of the 
gastrointestinal tract. One C. jejuni cdtB mutant was able to enteric colonization of SCID mice, 
but the invasiveness was impaired compared to wild-type bacteria, implying that CDT might 
have a role in the pathogenesis (invasion) of C. jejuni [144]. Moreover, an investigation of a  
C. jejuni cdtB mutant in wild-type and nuclear factor (NF)-κB deficient mice suggested that 
CDT may have a pro-inflammatory activity in vivo, as well as a potential role in the ability of  
C. jejuni to escape immune surveillance [145]. The cdtB mutant was less efficient than wild-
type cdtB in colonizing the wild-type mice but not in NF-κB deficient mice. Despite 100% 
colonization of the NF-κB deficient mice the cdtB mutant produced less gastritis than the wild-
type bacterium [145]. In 2008, Jain et al. showed that CDT producing C. jejuni strains adhered 
to and invaded epithelial cells more efficiently than CDT deficient C. jejuni strains by the use of 
the suckling mice model. They concluded that CDT is responsible for intestinal pathology and 
the colon is the major target.[146]. 
 H. hepaticus is an enterohepatic pathogen of mice that colonize the lower gastrointestinal 
tract and the liver, and HhCDT is reported to contribute to an increased mucosal inflammation 
or liver disease in susceptible mouse strains [147]. Young et al. provided evidence for a 
potential pro-inflammatory activity of CDT when they described that strains of H. hepaticus 
 29 
which expressed a functional CDT caused severe colitis in a murine model of inflammatory 
bowel disease, using IL-10 deficient mice [148]. Recently, H. hepaticus CDT were shown to 
play an important role in promoting the progression of infectious hepatitis to pre-malignant, 
dysplastic lesions, in vivo [149]. 
 An E. coli strain that expressed the cdt genes from S. dysenteriae was reported to be able 
to induce watery diarrhea in a suckling mouse model and the toxin caused a certain damage in 
the descending colon of these mice [150]. 
7.5. ANTIBODY RESPONSE TO CDT 
Very little is known about the HdCDT specific antibody response in humans. Purvén et al. 
detected cytotoxin neutralizing antibodies in the majority of sera from patients with culture-
proven chancroid [69]. CDT neutralizing antibodies were also detected in sera from patients 
infected with C. jejuni [151].When the prevalence of antibodies to HdCDT and the individual 
components were studied, the antibody levels were found to be significantly higher in both 
chancroid and periodontitis patients as compared with Tanzanian blood donors [70]. Moreover, 
antibodies to CdtC were less frequently detected than CdtA and CdtB antibodies; however they 
correlated well with the neutralizing capacity of the sera. These data suggest that the level of 
anti-HdCDT antibodies and their neutralizing capacity may be insufficient for induction of 
protective immunity [70]. Earlier this year Xynogala et al. detected antibodies to AaCDT with 
neutralizing capacity in human subjects infected with A. actinomycetemcomitans, thus 
demonstrating that AaCDT is produced during natural infection of humans [152]. Furthermore, 
20 of 23 human subjects with localized aggressive periodontitis were found to be unable of 
mounting a significant anti-CDT response and the authors suggested that this may in part 
explain their relative susceptibility to the disease. 
 Nevertheless, experimental infection with toxin producing H. ducreyi or immunization 
with bacterial sonicate, purified HdCDT or HdCDT components in the temperature dependent 
rabbit model resulted in the development of toxin neutralizing antibodies, although levels were 
low [120]. Moreover, Lagergård et al. immunized mice with formaldehyde detoxified HdCDT 
and high levels of toxin neutralizing antibodies were generated [153].  
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AIMS OF THIS STUDY 
 
THE GENERAL AIM OF THIS THESIS WAS TO INVESTIGATE THE ROLE OF HAEMOPHILUS DUCREYI 
LIPOOLIGOSACCHARIDE (HDLOS) AND HAEMOPHILUS DUCREYI CYTOLETHAL DISTENDING 
TOXIN (HDCDT) IN ANTIBODY RESPONSES. 
 
THE SPECIFIC AIMS WERE: 
 
1. TO EVALUATE THE FUNCTION AND VIABILITY OF HUMAN MONOCYTE-DERIVED-DENDRITIC 
CELLS, MACROPHAGES AND CD4+ T-CELLS AFTER INTERACTIONS WITH H. DUCREYI BACTERIA, 
HDLOS AND HDCDT, IN VITRO (PAPER I). 
 
2. TO DEFINE IMMUNOGENIC AND ADJUVANT PROPERTIES OF HDLOS (PAPER II AND III). 
 
3. TO EVALUATE THE IMPACT OF HDCDT ON THE SERUM ANTIBODY RESPONSES USING A 
MOUSE MODEL (PAPER III).  
 
4. TO DEFINE A PROCEDURE FOR THE GENERATION OF HIGH ANTIBODY LEVELS TO HDCDT IN 
THE GENITAL TRACT USING A MOUSE MODEL (PAPER III).  
 32 
 33 
MATERIALS AND METHODS 
REAGENTS (I AND II) 
Recombinant human GM-CSF (rhGM-CSF; 1.665 × 10
6
 U/ml, 150 μg) and IL-4 (rhIL-4; 2.9 × 
10
4
 U/μg, 25 μg) were purchased from R&D Systems (Abingdon, UK).  
Phytohemagglutinin (PHA) and trypan blue were obtained from Sigma Chemical Co. (St. Louis, 
MO, USA). [
3
H]-thymidine was purchased from Amersham (Buckinghamshire, UK). 
The oligosaccharide derivatives conjugated to human serum albumin (HSA), lacto-N-
neotetraose-APD-HSA conjugate (Gal-β1-4GlcNAc-β1-3Gal-β1-4(Glc)-APD-HSA) and 
monosialyl-lacto-N-neotetraose-APD-HSA conjugate (αNeu5Ac2-3Gal-β1-4GlcNAc-β1-3Gal-
β1-4(Glc)-APD-HSA), and oligosaccharides Lacto-N-neotetraose, LNnT (Galβ1-4GlcNAcβ1-
3Galβ1-4Glc) and 3‟sialyllactose (αNeu5Ac2-3Galβ1-4Glc) were obtained from IsoSep 
(Tullinge, Sweden). Lipid A-Kdo-Kdo (di[3-deoxy-D-manno-octulosonyl]-lipid A, ammonium 
salt) purified from heptose-deficient E. coli mutant WBB06 was obtained from Avanti Polar 
Lipids (Alabaster, AL).  
Flourescein isothiocyanate (FITC) was purchased from Sigma-Aldrich Inc. (St Louis, USA). 
BACTERIAL STRAINS, CULTURE CONDITIONS AND LABELING (I, II AND III) 
H. ducreyi strains used in this thesis were CCUG 4438 Institute Pasteur Collection (CIP) 542 
CCUG 7470 [Institute Pasteur Collection (CIP) 76118] obtained from the Culture Collection, 
University of Gothenburg (CCUG) and ATCC 35000 obtained from the American Type Culture 
Collection. 
 Bacteria were cultivated on chocolate agar plates Grand Lux (GL) (Department of 
Bacteriology, University of Gothenburg, Sweden) or in brain heart infusion (BHI) broth 
supplemented with 1% hemin/histidine (BHI-hemin; Sigma), 0.04% L-histidine (Fluka Chemie 
AG, Buch, Switzerland), 10% calf serum (FCS), 1% IsoVitale X, and 3 μg/ml vancomycin 
(Department of Bacteriology, University of Gothenburg, Sweden) as described previously [35]. 
Plates and liquid cultures were incubated in an oxygen-depleted, CO2-enriched humidified 
atmosphere at 33°C for 15-18 h in an anaerobic jar with anaerocult C (Merck, Darmstadt, 
Germany), bacteria cultivated in liquid medium were rotated at 100 rpm. 
Non-capsulated H. influenzae CCUG 7566 was cultivated on GL plates at 37 °C for 24 h in a 
CO2-enriched atmosphere. 
 Bacteria were labeled with FITC as described previously [61]. Briefly, bacteria grown in 
liquid medium for 15-16 were washed with PBS twice and killed with gentamycin treatment, 
followed by centrifugation and resuspension in 2 ml PBS containing 1mg/ml of FITC. After 
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incubation at 4°C for 1h bacteria were washed and the labeled bacteria were blocked with a 
balanced saline solution containing 0.1% gelatine (GH-BSS) and stored at -20°, until used. 
CELLS AND CULTURE CONDITIONS 
All cell cultures were maintained at 37°C in a humidified atmosphere with 5% CO2, as described 
[140]. 
CELL LINES (I, II AND III) 
Human: Epithelial cell line HeLa (ATCC
®
 CCL2
TM
) was cultured in Earle Minimum Essential 
Medium supplemented with 8% FCS, 0,02 mg/ml gentamicin, 2 mM L-glutamine. The 
keratinocyte cell line HaCaT (from Dr. N. E. Fusenig, Heidelberg, Germany) and normal foetus 
fibroblasts (Department of Virology, University of Gothenburg, Sweden) were cultured in 
Eagle‟s medium with 10% FCS, 1% glucose, 1% Na-pyruvate, 1% L-glutamine, and 1% 
penicillin-streptomycin (PEST). The primary human umbilical vein endothelial cells (HUVEC; 
Cascade Biologics Inc., Portland, OR, USA) were cultured in medium M200 (Cascade 
Biologics). 
Mouse: B-cell line X16 (ATCC
®
 TIB-209
TM
), T-cell hybridoma 3DO54.8, dendritic cell line 
FSDC [154], macrophage cell line P388D1 (ATCC
®
 CCL-46
TM
) and lung epithelial cell line 
MLE12 (ATCC
®
 CRL-2110
TM
) were cultured in Iscove´s Modified Dulbecco´s Medium 
(GIBCO
TM
) supplemented with 10% foetal calf serum (FCS) and 0,02 mg/ml gentamycin. The 
intestinal epithelial cell line m-ICc12 was maintained as described [155]. 
PBMC (II) 
Peripheral blood mononuclear cells (PBMC) were separated from heparinized blood samples 
from volunteer donors by density gradient centrifugation on Ficoll-Paque
TM
 Plus (Amersham 
Biosciences AB, Sweden) and cultivated in RPMI 1640 with 5% heat-inactivated (at 56 C for 30 
min) human AB serum, as described [61]. Viability, assayed by the trypan blue exclusion test, 
was >95%.  
GENERATION OF MONOCYTE DERIVED DCS AND MQS (I) 
Monocytes were purified from PBMCs by two different methods. In the first method CD14 
MicroBeads (Miltenyi Biotech, Germany) were employed according to the manufacturer‟s 
instructions. The second method utilized cell adherence to cell culture plates, which were 
incubated 37 C for 2h at in 5% CO2, then washed twice with PBS to remove the non-adherent 
cells.  
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DCs were generated by cultivation of the monocytes for 5 days in RPMI supplemented with 5% 
heat-inactivated human AB serum, 0.3 mg/ml L-glutamine, 0.1 mg/ml gentamycin, 800 U/ml 
GM-CSF and 1000 U/ml IL-4 [56]. For the generation of MQs was the RPMI medium 
supplemented with 5% FCS and the cells were cultivated for 7 days [156-157]. Surface markers 
on the DC and MQ populations were analyzed by flow cytometry after staining with antibodies 
against CD11c and CD14 [156]. The percentages of DCs expressing CD11c
+
 were 79–87% and 
95% for DCs that were derived from adherent and CD14 MicroBead purified monocytes, 
respectively. The percentage of CD14
+
 MQs was 89–94%. The DCs and MQs used in the 
experiments were from populations in which ≥79% of the cells were CD11c+ or CD14+. Cell 
viability was determined at the start of each experiment by the trypan blue exclusion test and 
was > 90%. There were no significant differences in purity, expression of surface marker or 
cytokine production between the DCs generated from monocytes purified by different methods. 
A higher number of DCs were generated from adherent monocytes after maturation, thus was 
this method applied for the production of DCs. 
CD4+ T-CELLS (I) 
CD4
+
 T-cells were isolated from heparinized blood samples from volunteer donors using  
CD4
+
 cell isolation kit (Dynal Biotech ASA (Oslo, Norway). 
ANTIGEN PREPARATIONS 
All protein determinations in this thesis were done using the Bio-Rad colorimetric assay with 
bovine serum albumin as standard. 
HDCDT PURIFICATION, CHARACTERIZATION AND LABELING (I AND III) 
The HdCDT complex was purified from E. coli, HdCdtA, HdCdtB, and HdCdtC recombinants 
as described previously [38]. Briefly, the HdCDT complex was reconstituted by immobilizing 
Glutathione S-transferase (GST)-HdCdtB fusion protein on a 5-ml GST HI-trap column 
followed by the addition of pre-mixed sonicate from E. coli (pAF-tac1) HdCdtA and HdCdtC 
recombinants. The HdCDT toxin complex was cleaved from the column by the addition of 
thrombin, which cleaves of the complex leaving the GST moiety on the column. The purified 
HdCDT preparation contained all the HdCdtA, HdCdtB, and HdCdtC subunits, as detected by 
SDS-PAGE followed by Coomassie blue staining and immunoblotting. The cytotoxic activities 
of the HdCDT preparations ranged from 10
6
 to 10
8 
cytopathic units per ml (CPU/ml), with  
1 CPU being defined as the dilution of the HdCDT preparation that caused 50% inhibition of 
HeLa cell growth compared to a PBS-treated control [39]. The endotoxin content, as quantified 
by the Limulus amoebocyte lysate assay (LAL, Sigma), was <0.05 μg/1 mg protein [158]. 
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 HdCDT was labeled using Alexa Fluor 488 protein labeling kit according to manufactures 
instructions (Molecular Probes Europe BV, Leiden, The Netherlands). The cytotoxic activity 
after the labeling procedure was decreased by 10%. 
 The toxicity of HdCDT was neutralized by the incubation of HdCDT at concentrations 
ranging from 3-30 ng/ml with rabbit anti-HdCDT serum at 37° for 60 min [38]. 
HDCDT TOXOID PREPARATION (III) 
Formaldehyde treatment of HdCDT was carried out as described [38]. The purified HdCDT 
preparation was diluted to 0.5 mg protein/ml in phosphate-buffered saline that contained 25mM 
lysine, and formaldehyde solution (formalin) was slowly added with stirring at the room 
temperature to a final concentration of 0.75 %. The mixture was incubated for 12 h at room 
temperature followed by 24 h at 37 
◦
C and then 24 h at 4 
◦
C, and was then extensively dialyzed 
against sterile PBS at 3–8 ◦C. The toxoid preparation was completely detoxified as estimated by 
cytotoxicity assay. The SDS-PAGE followed by Coomassie blue staining and immunoblotting 
showed similar pattern as described [153]. The final protein concentration was 225 µg/ml. 
H. DUCREYI LIPOOLIGOSACCHARIDE PREPARATIONS (I, II AND III) 
HdLOS7470 was hydrolyzed by using acetic acid or anhydrous hydrazine. In the first method, 
LOS was treated with 1% acetic acid at 100°C for 60 min, ultra centrifuged (35000 rpm for 5 h), 
and the carbohydrate-containing supernatant was fractionated on a Bio-Gel P-4 column  
(1.0  100 cm) in 0.05 M pyridine acetate buffer, to obtain an oligosaccharide (OS) preparation. In 
the second method, LOS was treated with anhydrous hydrazine (10 mg/ml) at 37°C for 30 min, 
to remove O-linked fatty acids, then precipitated with acetone on ice, cooled to -20°C, 
centrifuged, washed twice with cold acetone, re-suspended in water and freeze-dried (LOS-H). 
H. DUCREYI HEAT SHOCK PROTEIN (HSP) PREPARATION (III) 
HSP GroEL 58.5- kDa was purified from H. ducreyi strain 7470 as described previously with 
minor modifications [159]. Briefly, bacteria were re-suspended in PBS, vortexed with glass 
beads and centrifuged at 9300 x g for 20 min. The supernatant was applied to an ion-exchange 
column (Mono Q; Amersham Biosciences), the 58.5-kDA protein was eluted with 0.2 M NaCl 
and applied to a Sephadex 200 column (Amersham Bioscience). Fractions were pooled and 
concentrated using a Vivaspin column, with a molecular weight cut-off of 10,000 kDa 
(Vivascience, Hannover, Germany). At all stages, the HSP-containing fractions were monitored 
by dot-blotting or by SDS-PAGE and immunoblotting with the anti-HSP monoclonal antibody 
B11 (kindly provided by Dr C.A. Ison). The final protein concentration was 250 µg/ml. 
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CELL METHODS 
PHAGOCYTOSIS ASSAYS (II)  
Phagocytosis of FITC-labeled gentamycin-killed H. ducreyi by DCs and MQs was done using 
Phagotest according to the manufacturer‟s instructions (Orpegen Pharma, Heidelberg, Germany) 
and measured by flow cytometry (FACS; Becton Dickinson, San Jose, CA) as described 
previously[61]. Briefly, 100 μl of DCs or MQs (8 × 105 cells) were mixed with 20 μl  
(1 × 10
9
 CFU/ml) of FITC-labeled bacterial suspension; at a ratio of approximately 1:25and 
incubated at 37°C for 60 min. The FITC-labeled Escherichia coli provided with the assay kit 
were used as control and a non-capsulated strain of H. influenzae was used for comparison. 
Samples were analyzed by flow cytometry with blue–green excitation at 488 nm using an argon 
ion laser and FACSCalibur CellQuest software. The cell populations were analyzed by means of 
forward and side light scatter. A live gate was set in the red fluorescence FL2 histogram, and a 
marker was set in the histograms, i.e. the fluorescence intensity (FL1) of the control sample in 
order to exclude background cell auto-fluorescence. The percentages of cells having ingested 
bacteria as well as their mean values for the FL1 channel were recorded. The mean and standard 
deviation (mean ± S.D.) of three independent experiments were calculated. A cell population 
that was exposed to labeled bacteria at 0°C was used as the negative control, and this value was 
subtracted from the test results, to exclude the background. 
CYTOKINE ASSAYS (II) 
The culture supernatants from APCs, keratinocytes, endothelial and epithelial cells and 
fibroblasts were collected after 24 h of incubation with the bacteria or bacterial antigens, and 
assayed for IL-1β, IL-6, IL-8, TNF-α, and IL-12. The culture supernatants from DCs that were 
stimulated first with H. ducreyi for 24 h and then treated with different doses of HdCDT and 
reverse were tested after 48 h for IL-12 production. 
The culture supernatants from antigen-pulsed APCs that were co-cultured with CD4
+
 T-cells 
were collected after 48 h, and the levels of IL-4, IL-13 and IFN-γ were measured. ELISAs with 
specific capture and detection antibodies were used to measure the cytokine levels. The levels of 
IL-1β, IL-6, IL-8 and TNF-α were determined by ELISA (R&D Systems). For IL-4, IL-12,  
IL-13 and IFN-γ, Opt EIA kits (BD Pharmingen, Heidelberg, Germany) were used. All of the 
cytokines were analyzed in three separate experiments. 
HDCDT INDUCTION OF DC APOPTOSIS (II) 
DC apoptosis was measured after treatment with 0.5 μg/ml of HdCDT for 24, 48 and 72 h. 
Apoptosis was estimated by two-color flow cytometry using annexin V-FITC (PharMingen, San 
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Diego, CA) and propidium iodide (PI, Sigma), as described [160]. Annexin V binds to 
phosphatidylserine that is translocated during apoptosis from the inner to the outer leaflet of the 
plasma membrane. Live cells with intact membranes are distinguished by their ability to exclude 
PI, which readily penetrates dead or damaged cells. Readings at 488 nm excitation and 525 nm 
(PI: 625 nm) emission wavelengths were recorded using the FACStar flow cytometer (Becton 
Dickinson Biosciences, San Jose, CA), and the subsequent analysis was performed using the 
CellQuest Pro software (Becton Dickinson). Dual analysis was introduced using a quadrant dot 
plot, in which „necrotic cells‟ were identified as single PI-positive, „early apoptotic cells‟ were 
annexin V-FITC-positive only, and cells in „late apoptosis‟ were recognized as double-positive 
for annexin V-FITC and PI. Cells that stained negative for both annexin V-FITC and PI were 
classified as live cells. The number of cells in each category was expressed as a percentage of 
the total number of stained cells counted.  
CYTOTOXIC ANALYSES (III) 
Time and dose dependent effects of treatment with HdCDT on the cell lines; HeLa, FSDC, 
P388D1, MLE12, m-ICc12, X16 and 3DO54.8 with HdCDT were examined by microscopy as 
described [115, 120, 159]. Briefly, 100µl of cells were seeded in 96-well plates at a density of 
4x10
4
 cells /ml (adherent cell lines HeLa, FSDC, P388D1, MLE12 and m-ICc12 were allowed to 
adhere over night), and HdCDT (0.1, 1, 10, 50, 100, 200 and 1000 ng) was added to the cells. 
Further, the cytotoxic effect was measured with MTT assay at the time points 24, 48 and 72 h. 
MTT ASSAY (III) 
The colorimetric MTT assay is based on the cleavage of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyl tetrazolium bromide (MTT) into water insoluble crystals of formazan by metabolically 
active cells as described previously [140]. 50µg of MTT was added to the HdCDT treated cells, 
described above, which were further incubated at 37º for 4h. The formazan crystals were 
dissolved by the addition of 100µl acidic isopropanol (0.1 N HCl) (MERCK KgaA, Darmstadt, 
Germany) and the absorbance was measured on BioTek Power Wave xs at the wavelengths  
570 nm and 630 nm. The difference in absorbance at the two wavelengths is calculated and the 
result is expressed as per cent of the control cell (untreated) absorbance. 
CELL CYCLE ANALYSIS (III) 
The effect of HdCDT intoxication on cell cycle progression in the cell lines; 3DO54.8, X16, 
MLE12 and HeLa was monitored using flow cytometry analysis of the DNA content [140]. 
Cells were seeded in 24-well plates at a density of 1x10
5
 cells /ml and intoxicated with different 
concentrations of HdCDT (50, 100 and 500 ng) for 24 h, followed by centrifugation, one wash 
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with PBS and fixation in 1 ml ice cold 70% ethanol on ice for 15 min. The cells were then re-
suspended in 300µl PI solution (0.05 mg/ml PI; 0.02 mg/ml RNase; 0.3% Igepal; 1 mg/ml 
sodium citrate) and re-incubated for 1 h on ice. Flow cytometry analysis was performed with 
FACSCalibur (Becton Dickinson, San Jose, CA, USA). Data was collected from 10
4
 cells and 
analyzed using FlowJo (Becton Dickinson). 
HDCDT INTERNALIZATION BY CONFOCAL MICROSCOPY (III) 
The internalization of Alexa Fluor 488 labeled HdCDT in mouse and human epithelial cell lines 
was followed by Confocal Laser Scanning Microscopy. MLE12, m-ICc12 and HeLa cells at a 
density of 1x10
5
 were seeded in glass bottom microwell dishes (MatTek Corporation. Ashland, 
USA). After overnight incubation the cells were washed with PBS and incubated for 5 or 10 min 
at 37
o
C with Alexa Fluor 488 labeled HdCDT, (HeLa 10 µg HdCDT for 5 min, MLE12 and  
m-ICc12 30 µg HdCDT for 10 min), thereafter unbound toxin was removed by washing twice 
with medium. The internalization of the toxin in live cells was followed at 37º for 48 h using 
Confocal Laser Scanning Microscopy (Swegene Center for Cellular Imaging, Gothenburg 
University, Sweden). 
IMMUNIZATION OF MICE (II AND III) 
Paper II 
Six to eight week old NMRI (wild-type), BALB/c, C57BL/6, athymic nu/nu mice obtained from 
B&K Universal AB, Sollentuna, Sweden. Toll-like receptor 4 knockout (TLR4 KO) and 
myeloid differentiation factor 88-knockout (MyD88 KO) mice on a C57BL/6 background, 6-8 
weeks of age, were derived by Shizuo Akira (Department of Host Defense, Research Institute 
for Microbiological Diseases, Osaka University, Japan) and provided by Dr. Mary-Jo Wick 
(Department of Microbiology and Immunology, Gothenburg University, Sweden). Mice in 
groups of 5-12 were immunized subcutaneously (sc) on three occasions at 2-week intervals with 
purified HdLOS7470, OS, LOS-H (5 μg/dose); lacto-N-neotetraose-APD-HSA and monosialyl-
lacto-N-neotetraose-APD-HSA conjugates (2.5 μg sugar/dose); bovine serum albumin (BSA)  
(5 μg/dose) alone or together with HdLOS7470 (1 μg or 5 μg/dose); or were hyper-immunized 
with H. ducreyi 7470 bacteria that were boiled for 1 h. The hyper-immunization was performed 
with increasing amount of bacteria, injected 9 times, two times sc and 7 times intraperitoneally. 
Paper III 
Balb/c mice (female) at 6-8 weeks of age obtained Taconic (Denmark). Mice in groups of 5-12 
were immunized subcutaneously (sc) 2 - 4 times, 2 weeks apart with; BSA (5 µg/dose) alone or 
together with HdCDT (5 µg/dose); H. ducreyi 4438 (10
6
 CFU/dose) alone or together with 
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HdCDT (10µg/dose); HdCDT (5µg/dose) alone or together with HdLOS7470 (5µg/dose); 
HdLOS7470 (5µg/dose), HdCDT toxoid (10µg/dose); HdCDT toxoid (10µg/dose) + RIBI 
adjuvant system (Monophosphoryl Lipid A and synthetic trehalose dicornomycolate, Corixa, 
USA) prepared and mixed according to manufactures instructions or HdCDT toxoid 
(10µg/dose) + Imject® Alum (aluminum hydroxide and magnesium hydroxide, Pierce, USA), 
diluted 1:5 and mixed 1:2 with toxoid preparation according to manufactures instructions. 
 Mice were sacrificed 10 days after last immunization, sera and genital tissue were 
collected. Sera were stored at-20°until used. Genital tissue was stored at -20° in 270 µl PBS 
solution containing 2mM phenylmethylsulfonylflouride (Sigma-Aldrich Inc, St Louis, USA), 
0.1 mg/ml soybean trypsin inhibitor (Sigma-Aldrich Inc, St Louis, USA) and 0.05 mM EDTA. 
Antibodies were extracted from the tissue through permeabilization by addition of saponin 
(Sigma), to a final concentration of 10% and incubation at 4°over night followed by 
centrifugation (15.5 k x g, 10 min) [161]. Pre-immune sera were obtained from naive mice.  
 
During experiments animals were maintained at the Department of Experimental 
Biomedicine, at University of Gothenburg under pathogen free conditions. Experiments were 
carried out with the approval of the Ethical Committee for Laboratory Animals in Gothenburg. 
ANTIBODY ANALYSIS 
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) (II AND III) 
Antibodies to BSA, HSP, HdLOS, HdCDT and whole bacteria were assayed by ELISA, as 
described [153, 162]. Briefly, 96-well Maxisorp plates were coated with 10 µg/ml of BSA,  
1.5 µg/ml HSP, 10 µg/ml HdLOS, 1.5µg/ml of HdCDT or 5 μg/ml sialyl/neolactotetra 
conjugated to HSA, in phosphate-buffered saline (PBS). For the estimation of antibodies to 
bacteria, plates were pre-coated with poly-lysine (10ug/ml) for 30 min, then 10
10
 H. ducreyi 
bacteria/ml were added and fixed with 0.5% glutaraldehyde solution, as described [162]. Sera 
were added at a1:10, 1:20 or 1:100 dilution in the first well and then diluted three-fold in 0.1 % 
BSA–PBS or 0.05% Tween-PBS (for BSA and HdLOS). In Paper I was a pool of three sera 
induced by HdLOS (diluted 1:100) selected as reference serum for estimation of anti-LOS 
antibodies, and assigned a value of 100 units/ml (corresponding to an end point titer of about 
1:700). Similarly, for estimation of anti-BSA antibodies were a pool of three sera against BSA 
(diluted 1:500) used as reference (100 units/ml corresponding to an end point titer of 1:50 000). 
The antibody concentrations were evaluated using reference line analysis according to the 
reference sera, and 10 units/ml was the lowest value giving reproducible results. The levels of 
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IgG subclasses and of the antibodies to sialyl/Neo-lactotetra are expressed as end-point titer, a 
reciprocal serum dilution that gives an absorbance of 0.3 at 405 nm. A titer of <10 was 
considered to be a negative value. 
In Paper II was a pool of mouse immune serum containing antibodies against BSA, HSP, 
HdLOS7470 or HdCDT selected as a reference and included on all the plates coated with BSA, 
HSP, HdLOS7470 or HdCDT, respectively. For detection of IgG antibodies alkaline 
phosphatase conjugated AffiniPure Goat–anti–mouse IgG (high+low) (Jackson 
ImmunoResearch Laboratories Inc. USA) was used at a dilution of 1:2000 and for the detection 
of IgG subclasses alkaline phosphatase conjugated Goat Anti–Mouse IgG1, IgG2a, IgG2b and 
IgG3 (SouthernBiotech, Birmingham, Alabama, USA) was used at a dilution of 1:1000. The 
plates were developed by the addition of p-nitrophenyl phosphatase (NPP) substrate (Sigma-
Aldrich Inc, St Louis, USA). The absorbance was measured at 405 nm. Results are expressed as 
end point titer which is the value that corresponds to the serum dilution giving an absorbance 
value of 0.2 above background. 
LOS ANTIBODY INHIBITION STUDY (II) 
Inhibition was performed by mixing of diluted anti-HdLOS 7470 serum with an equivalent 
volume containing 5, 25 or 100 μg of HdLOS7470; HdLOS4438; Lacto-N-neotetraose; 
3‟sialyllactose as inhibitor or PBS as control. The antibodies in the mixtures were first incubated 
for 2 h at 37°C and then for 24 h at +4°C in order to allow the adsorption of the antibodies to the 
antigen, followed by centrifugation and antibody estimation of the supernatant by ELISA. The 
percentage of inhibition was defined as % of OD in diluted and absorbed serum compared to the 
same serum diluted and mixed with PBS (1-A405 of adsorbed serum/A405
 
of serum with PBS) × 
100%.  
THIN-LAYER CHROMATOGRAM (TLC) BINDING ASSAYS (II) 
The binding of the anti-LOS antiserum to purified glycosphingolipids with structures related to 
the terminal carbohydrate sequences found in HdLOS was tested with;  
GM3 ganglioside (NeuAc3Gal4Glc1Cer; terminal sialyl-lactose sequence);  
lactosylceramide (Gal4Glc1Cer; terminal lactose sequence); sialyl-neolactotetraosylceramide 
(NeuAc3Gal4GlcNAc3Gal4Glc1Cer; terminal sialyl-neolactotetra sequence); 
neolactotetraosylceramide (Gal4GlcNAc3Gal4Glc1Cer; terminal neolactotetra sequence); and 
the negative reference globotetraosylceramide (GalNAc3Gal4Gal4Glc1Cer) [163]. 
HdLOS7470 and HdLOS4438, as well as lipid A-Kdo-Kdo were used as positive references in 
the binding assays.  
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Polyclonal rabbit anti-mouse antibodies (DAKO, Glostrup, Denmark) were labelled with 125I 
using Na125I (100 µCi/ml; Amersham Pharmacia Biotech, Little Chalfont, UK), according to the 
protocol (Pierce, Rockford, IL), giving approximately 5 × 10
3
 cpm/µg protein. Binding of anti-
LOS serum to glycoshingolipids separated on TLC was performed as described [164]. 
INHIBITION OF TNF-α PRODUCTION BY LOS-STIMULATED HUMAN PBMCS USING A SPECIFIC 
HDLOS-ANTISERUM (II) 
PBMCs from four donors were treated separately with purified E. coli Ra strain LOS (Sigma), 
HdLOS4438 or HdLOS7470 at concentrations that ranged from 0.01 - 10 ng/ml. The LOS 
samples were pre-mixed with an equal volume of anti-LOS serum diluted 1:10, 1:50 or 1:100 
before they were added to the PBMCs. After 18 h, cells were centrifuged and supernatants were 
collected. The concentration of TNF-α in supernatant was measured with ELISA according to 
manufacturer (DuoSet ELISA Development System; R&D Systems, Abingdon, UK). 
TOXIN NEUTRALIZATION ASSAY (III) 
The level of HdCDT neutralizing antibodies was assayed as described before [69, 115]. Briefly, 
eight two-fold dilutions of sera in 50 μl of culture medium containing 2% FCS was incubated, in 
96-well tissue culture plates with the addition of 50 μl of HdCDT at a concentration of 
100µg/ml, for 2h and 15min. 100 µl of the mixture was then added to 24 h semi-confluent 
culture of HeLa cells (approximately 5×10
4
 cells/ml) in culture medium containing 8% FCS, 
after 2h of incubation at 37° C, medium was discarded and fresh medium was added. Toxin 
titrations, as well as control cells, were included in each test. The cells were stained with Giemsa 
after 72 h of incubation and examined under the microscope. The neutralization titer was 
defined as the dilution of serum that gave 50% cell growth as compared to the control.  
STATISTICAL ANALYSIS 
Statistical analyses were done using Prism Software System (GraphPad Software Inc., San 
Diego, CA). The relationship between ELISA antibody titers and neutralizing titers was 
evaluated using Pearson correlation test. Comparisons of different mice groups were performed 
using an unpaired t-test and values of P<0.05 were considered statistically significant. 
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RESULTS AND COMMENTS 
1. THE FUNCTION AND VIABILITY OF HUMAN MONOCYTE-DERIVED-DENDRITIC CELLS, 
MACROPHAGES AND CD4+ T-CELLS AFTER INTERACTIONS WITH H. DUCREYI BACTERIA, 
HDLOS AND HDCDT, IN VITRO (PAPER I) 
The specific antibody response is dependent on the presentation of antigens by antigen 
presenting cells (APCs), followed by the activation of a T-cell response. These are the initiating 
steps in the development of immune responses. In order to investigate the function and viability 
of APCs after interactions with H. ducreyi bacteria, HdLOS and HdCDT human derived cells 
were used, in vitro. 
1.1. PHAGOCYTOSIS OF H. DUCREYI BY DCS AND MQS 
The antigen presentation and the ability to activate a T-cell response are dependent on the 
capacity of APCs to phagocytose and present pathogen components. In order to evaluate the 
phagocytic ability of human monocyte derived DCs and MQs, three non-opsonized FITC-
labeled H. ducreyi strains, H. influenzae and E. coli were used. The DCs were found to ingest all 
three H. ducreyi strains and no significant differences were found in the percentages of 
phagocytosis between the different H. ducreyi strains, but there were significant differences in 
this respect between H. ducreyi 4438 and H. influenzae and E. coli (P = 0.03) (Tabel 2.).  
The correlation between phagocytosis by DCs and MQs was high (r = 0.9). The level of 
phagocytosis by DCs and MQs of the three H. ducreyi strains and the non-capsulated  
H. influenzae strain were similar, although the MQs had slightly better rates of bacterial uptake 
(Tabel 2.). 
 
Table 2. The percentages of DCs and MQs that phagocytosed FITC-labeled 
  bacteria at 37° C for 60 min as determined by FACS analysis 
Bacteria  
 
Mean* % of DCs with  
bacteria ± S.D.  
Mean* % of MQs with  
bacteria ± S.D.  
H. ducreyi 7470 15 ± 2.1 22 ± 11.1 
H. ducreyi 4438 27 ± 10.0 
a
 26 ± 15.5 
H. ducreyi 35000 13 ± 5.0 22.5 ± 6.3 
H. influenzae 8 ± 0.7 
b
 14.5 ± 7.7 
E. coli 6 ± 2.8 
c
 17 ± 12.7 
* Mean of three independent experiments; a versus b and c, P < 0.05. 
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1.2. PRO-INFLAMMATORY CYTOKINE PRODUCTION BY DC AND MQS AFTER INDUCTION BY  
H. DUCREYI BACTERIA, HDLOS AND HDCDT 
The activation of DC and MQs caused by H. ducreyi, HdLOS and HdCDT was studied by 
analyzing cell supernatant for the secretion of IL-1β, IL-6, IL-8, TNF-α, and IL-12 after 24 h of 
incubation, a non capsulated strain of H. influenza and V. cholerae LPS were used for 
comparison.  
 All of the H. ducreyi strains induced strong secretion by DCs of IL-1β, IL-6, IL-8, TNF-α, 
and IL-12 as compared to unstimulated DCs (P ≤ 0.05) (Fig 5A-E). In general, the H. ducreyi 
strains and H. influenzae induced similar secretion of cytokines. Although the induced cytokine 
level varied slightly among DCs from different donors the patterns of the cytokine responses to 
different antigens were similar. The level of IL-12 production by DCs stimulated for 24 h with 
either H. ducreyi or H. influenzae were high, ranging from 32 000 to 55 000 pg/ml; the 
corresponding level in HdLOS-stimulated DCs was about 8000 pg/ml (Fig 5E). The secreted 
level of IL-8 and TNF-α by DCs pulsed with bacteria were significantly higher than obtained 
after contact with LOS (P ≤ 0.05), indicating that components other than HdLOS are involved in 
determining the level of DC activation and production of cytokines. In addition, the induction of 
cytokine production by HdLOS and V. cholerae LPS were comparable (data not shown). 
 Stimulated MQs secreted high levels of cytokines e.g. a threefold increase in IL-6 and a 
fivefold increase in IL-8 were noted after 24 h of incubation with H. ducreyi, the level of IL-1β 
were overall low (data not shown). Moreover, MQs secreted a lower level of all the cytokines as 
compared with DCs. 
 The H. ducreyi strains used in this study were gentamycin-killed and consequently no 
HdCDT were secreted, therefore DCs and MQs were incubated with addition of purified 
HdCDT preparation. The only cytokine production induced by HdCDT was IL-8 and the 
secreted level was low (Fig 5C).  
Our results indicated that HdCDT inhibited the secretion of IL-12 by DCs. IL-12 is an 
important cytokine since it activates NK cells and induces the differentiation of CD4
+
 T-cells 
into Th1. Therefore, HdCDT treatment of DCs prior to bacterial stimulation was evaluated for a 
possible effect on the induction of IL-12 production by bacteria stimulated DCs. The highest 
dose of HdCDT used (0.5 µg) caused about 52% inhibition of IL-12 secretion as compared with 
bacteria-stimulated DCs (paper II). If the DCs instead were stimulated with bacteria first and 
then treated with 0.5 µg of HdCDT only 13% of the total IL-12 production was inhibited (data 
not shown), suggesting that complete inhibition of cytokine production in stimulated cells 
requires a high concentration of HdCDT. 
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Figure 5. IL-1β (A), IL-6 (B), IL-8 (C), TNF-α (D), and IL-12 (E) production by monocyte-
derived DCs that were co-cultured with different antigens. Cell viability, determined at the start 
of each experiment by the trypan blue exclusion test was greater than 90%. The following 
antigens were used: H. ducreyi CCUG 7470, CCUG 4438, ATCC 35000, H. influenzae,  
H. ducreyi LOS (1 μg/ml) or HdCDT (0.5 μg/ml). The culture supernatants were tested after 24 
h for IL-1β, IL-6, IL-8, TNF-α, and IL-12. The data represent the mean ± S.D. from three 
independent experiments. For the supernatants of bacteria-pulsed DCs versus non-pulsed DCs,  
P ≤ 0.05; for non-pulsed DCs versus LOS-pulsed DCs, P ≤ 0.05. 
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1.3. HDCDT ACTION ON DC VIABILITY AND APOPTOSIS 
In order to investigate the effect of HdCDT treatment on APCs, the viability of treated cells was 
investigated by trypan blue exclusion test and early and late apoptosis was detected by a 
combination of annexin V-FITC and PI staining. HdCDT treatment resulted in a slow successive 
decrease in DC viability over time. However, 50% of cells were still not stained with trypan 
blue after 3 days of incubation with 0.5 µg/ml of HdCDT. When apoptosis was evaluated,  
a significant and successive increase in the number of cells stained with annexin V-FITC was 
found, resulting in about 60% of the cells being stained with annexin V-FITC after 72h of 
HdCDT treatment (Fig 6). During the experimental period, only a low percentage of cells were 
stained exclusively with PI (necrotic cells).  
 These results indicate that HdCDT treatment induces early and late apoptosis in DCs, 
albeit slowly. It must though be mentioned that a high concentration of toxin was used in the 
experiment. 
 
 
 
Figure 6. Induction of early and late 
apoptosis in monocyte-derived DCs treated 
with 0.5 μg/ml HdCDT over 3 days. The 
data are expressed as the percentages of 
annexin V-stained cells in the total cell 
population, and represent the mean ± S.D. 
of triplicates. For the percentages of annexin 
V-stained cells at time 0 versus after 24 and 
48 h, respectively, P < 0.05 and P < 0.001.
 
1.4. ACTIVATION OF T-CELLS BY DCS AND MQS PULSED WITH H. DUCREYI, HDLOS AND 
HDCDT 
H. ducreyi and HdLOS induced secretion of regulatory and inflammatory cytokines by DCs and 
MQs. In order to evaluate the capability of the stimulated DCs and MQs to activate  
CD4
+
 T-cells, proliferation and cytokine secretion by the CD4
+
 T-cells were measured. 
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1.4.1. INDUCTION OF CD4+ T-CELL PROLIFERATION 
The viability of the DCs and MQs incubated with bacteria (H. ducreyi or H. influenzae) or 
HdLOS were not affected. DCs stimulated with H. ducreyi or H. influenzae significantly 
increased the CD4
+
 T-cell proliferation as compared with unstimulated or HdLOS stimulated 
DCs (Fig 7A). In addition, MQs stimulated with HdLOS induced higher level of T-cell 
proliferation than MQs stimulated with H. ducreyi. Proliferation was not improved in  
CD4
+
 T-cells incubated with the antigens alone (data not shown). In general proliferation of 
CD4
+
 T-cells were significantly induced by stimulated DCs, as compared with stimulated MQs. 
DCs and MQs stimulated with HdCDT were unable to induce T-cell proliferation (Fig 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. T-cell proliferation in response to 
DCs (A) and MQs (B) that were stimulated 
with bacteria or bacterial antigens. APCs 
were stimulated with gentamycin-killed  
H. ducreyi CCUG 7470, non-capsulated  
H. influenzae, H. ducreyi LOS (1 μg/ml), 
and HdCDT (0.5 μg/ml) for 2 days. 
Antigenpulsed DCs or MQs were washed, 
and cell viability was determined before co-
culturing with T-cells as being 85% after 
pipetting and harvesting of the cells. The 
CD4
+
 T-cells (1 × 10
5
 per well) were co-
cultured with APCs. After 6 days. T-cell 
proliferation was measured by the 
incorporation of [
3
H]-thymidine. The data 
represent the mean ± S.D. from three 
independent experiments. For T-cell 
proliferation induced by bacteria-pulsed 
DCs or MQs versus non-pulsed DCs or 
MQs, P <0.03; for T-cell proliferation 
induced by H. influenzae-pulsed DCs versus 
H. ducreyi, P 0.05; for T-cell proliferation 
induced by bacteria-pulsed DCs versus 
LOS-pulsed DCs, P <0.05. 
 
 
 48 
 In order to investigate whether HdCDT activity on antigen-stimulated APCs caused down 
regulation of the T-cell proliferation, DCs and MQs were first stimulated with HdLOS for 24h 
and then two different concentrations of HdCDT were added. The result indicated that the APC 
induced T-cell proliferation was partially blocked or abolished by the highest HdCDT dose  
(0.5 μg/ml) (Fig 8).  
 
 
Figure 8. Abolition of T-cell proliferation after contact with APCs that were stimulated with 
LOS and then treated with HdCDT. CD4
+
 T-cells (1×10
5 
per well) were co-cultured with DCs or 
MQs (1×10
4
 per well) that were treated with purified LOS (1 μg/ml for 24 h) and then treated 
with two concentrations (0.5 or 0.05 μg/ml) of HdCDT. The pulsed DCs were washed and 
transferred to a new tissue culture plate before co-culturing with the T-cells. After 6 days of co-
cultivation, T-cell proliferation was assessed by measuring the incorporation of [
3
H]-thymidine. 
The data represent the mean ± S.D. from three independent experiments. For T-cell proliferation 
induced by DCs that were treated with LOS alone versus DC that were treated with LOS and 
different concentrations of HdCDT, P 0.01.  
 
 The specificity of the effect caused by HdCDT on the DCs capacity to activate T-cell 
proliferation was investigated by neutralizing of active HdCDT with toxin specific hyper-
immune rabbit serum. DCs were pulsed with the neutralized HdCDT before co-cultivation with 
the CD4
+
 T-cells. The T-cell proliferation was increased 1.6–2.3-fold when active HdCDT was 
neutralized, indicating that the effect was HdCDT specific (data not shown). 
 In summary, these results indicate that HdCDT might influence the function of the APCs 
by causing apoptosis and decreases in cytokine production especially IL-12, provided a 
sufficient amount of toxin is available. 
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1.4.2. CYTOKINE SECRETION BY CD4+ T-CELLS 
To determine if the T-cell response generated by H. ducreyi and its antigens was of a Th1-type 
or a Th2-type the secretion of IL-4, IL-13 and IFN-γ was measured in the culture supernatants of 
CD4
+
 T-cells co-cultured with DCs or MQs previously stimulated with bacteria, HdLOS, or 
HdCDT (Fig 9).  
 High levels of IFN-γ (up to 3300 pg/ml), but not of IL-4 or IL-13 were secreted by  
CD4
+
 T-cells after contact with DCs stimulated with H. ducreyi bacteria. DCs alone produced 
low levels of IFN-γ, ranging from 400 to 600pg/ml, after stimulation with different H. ducreyi 
strains (data not shown), which indicates that this cytokine was secreted mainly by  
CD4
+
 T-cells. Low levels of cytokines were detected in the culture supernatants of CD4
+
 T-cells 
that were co-cultured with DCs stimulated with HdLOS or HdCDT (Fig 9A). 
 
 
 
 
 
 
Figure 9. IL-4, IL-13 and IFN-γ production 
by CD4
+
 T-cells that were co-cultured with 
DCs (A) or MQs (B) that had been pulsed 
with the following antigens: gentamycin-
killed H. ducreyi CCUG 7470, non-
capsulated H. influenzae, H. ducreyi LOS  
(1 μg/ml) or HdCDT (0.5 μg/ml) for 2 days. 
Antigen-pulsed DCs or MQs were washed; 
cell viability was determined by trypan blue 
exclusion test, being 85% after pipetting and 
harvesting of cells. The CD4
+
 T-cells 
(1×10
5
 per well) were then co-cultured with 
antigen pulsed DCs or MQs  
(1×10
4
 per well). The culture supernatants 
were tested after 48 h of co-culturing for the 
presence of IL-4, IL-13, and IFN-γ. The 
supernatants from unstimulated DCs or 
MQs that were co-cultured with T-cells 
were used as the negative controls. The data 
represent the mean ± S.D. of three 
independent experiments. For IFN-γ 
production induced by bacteria-pulsed DCs 
or MQs that were co-cultured with T-cells 
versus non-pulsed DCs or MQs, P <0.05. 
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 Similarly, CD4
+
 T-cells that were co-cultured with MQs stimulated with HdLOS,  
H. ducreyi or H. influenzae bacteria, secreted significantly higher concentrations of IFN-γ than 
of IL-4 and IL-13 (Fig 9B). However, CD4
+
 T-cells that were co-cultured with stimulated MQs 
secreted about 10-fold lower levels of all the cytokines tested, as compared with co-culture with 
stimulated DCs. Furthermore, no significant increase in the levels of IL-4, IL-13, and IFN-γ 
were detected in the culture supernatants of CD4
+
 T-cells that were co-cultured with HdCDT 
treated DCs or MQs. 
 IFN-γ was found to be the predominantly secreted cytokine by CD4
+
 T-cells after  
co-culture with APCs stimulated with H. ducreyi bacteria and this result strengthens the 
hypothesis of a Th1-type immune response at least in the early stages of H. ducreyi infection.  
2. IMMUNOGENIC AND ADJUVANT PROPERTIES OF HDLOS (PAPER II AND III) 
LPS is a T-cell independent antigen that is able to directly activate B-cells in the absence of  
T-cells. Antibodies directed against the O-side part of the LPS are bactericidal for many Gram-
negative bacteria. HdLOS induces inflammatory responses, as described above. In addition 
specific antibodies may play a role in protection against bacteria, therefore the immunogenic 
and adjuvant properties of HdLOS were evaluated. 
2.1. IMMUNOGENICITY OF PURIFIED HDLOS 
To investigate the immunogenicity of HdLOS and host parameters involved in the antibody 
response, mice of different strains were used; the outbreed strain NMRI and the inbreed strains 
BALB/c (good antibody producer and Th2 responder) and C57BL/6 (good cell mediated 
immunity and Th1 responder), and the genetically modified strains nu/nu (athymic mice), 
TLR4-KO (Toll-like receptor 4 receptor deficient) and MyD88-KO (TLR adaptor deficient). 
 Immunization with purified HdLOS7470 or HdLOS4438 induced strong serum IgG 
antibody responses of 10 000-12 000 units/ml in NMRI and BALB/c mice while a significantly 
lower responses (P=0.002) was detected in C57BL/6 mice (Fig 10A). As expected, the athymic 
nu/nu mice respond with IgM antibodies only (Fig 10B). 
 Furthermore, the IgG subclass distribution in sera was investigated for NMRI and BALB/c 
mice and the highest levels were noted for IgG1/IgG2b and IgG2b, respectively. Fig 10C shows 
the IgG subclass distribution in BALB/c mice. In addition, no antibody response to HdLOS was 
detected in mice that lacked either functional TLR4 or MyD88 (Fig. 10A and B).  
In summary, HdLOS was found to be an immunogenic T-cell independent antigen, which 
was dependent on the TLR4 and MyD88 signaling pathway.  
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Figure 10. Antibody response in mice 
immunized with purified LOS 7470. (A) 
IgG and (B) IgM antibody response in 
different mice strains after immunization 
with purified 7470LOS and (C) IgG 
subclass response in BALB/c mice 
immunized with LOS 7470. Outbreed, 
NMRI; inbred, BALB/c (good antibody 
producers and Th2 responders), C57BL/6 
(good cell mediated immunity and Th1 
responders), nu/nu (athymic mice), TLR4-
KO (Toll-like receptor 4 receptor deficient) 
and MyD88-KO (TLR adaptor deficient) 
were immunized sc three times with 5 μg of 
purified LOS. The antibodies to LOS were 
estimated by ELISA and expressed in units 
per milliliter (A and B) or end point titers 
(C) according to the reference serum. In (A) 
and (B) the data are plotted as values for 
individual mice (n = 5) after subtraction of 
the respective mean values for the pre-
immune animals. A horizontal bar 
represents the mean value. In (C) the IgG 
subclass antibodies to 7470LOS are 
expressed as end point titer and represent 
the mean ± SEM (n = 10) after subtraction 
of a pre-immune mean value. NMRI vs. 
BALB/c, ns; NMRI vs. C57/BL6 P < 0.001 
(**); NMRI vs. nu/nu, P < 0.0001 (***) 
(unpaired t-test); BALB/c vs. NMRI, P < 
0.0001 (***); BALB/c vs. nu/nu, ns (not 
significant) (unpaired t-test). 
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 In order to characterize the LOS structure responsible for the induction of the anti-LOS 
antibody response, BALB/c mice were immunized with the oligosaccharide fraction of 
HdLOS7470 (OS) or with HdLOS7470 that had been hydrolyzed with anhydrous hydrazine in 
order to remove the O-linked fatty acids from lipid A (LOS-H) (Fig 11). Neither the 
oligosaccharide part nor the hydrazine treated HdLOS were able to induce a significant antibody 
response, as compared with pre-immune mice.  
 
 
 
 
 
Figure 11. The IgG antibody response to 
LOS7470 in BALB/c mice immunized with 
LOS7470, OS, LOS-H, or boiled H. ducreyi 
bacteria. Mice (n = 10) were immunized sc 
three times with 5 μg of different 
preparations of LOS and nine times with 
boiled H. ducreyi 7470 bacteria (in total  
2 × 10
12
 bacteria during 4 weeks of 
immunizations). The levels of antibodies to 
LOS7470 were estimated by ELISA and are 
expressed in units per milliliter according to 
the reference serum. The data are plotted as 
values for individual mice (n = 10) after 
subtraction of the respective mean values 
for the pre-immune animals. A horizontal 
bar represents the mean value. Pre-immune 
vs. anti-LOS serum P = 0.0001 (***);  
pre-immune vs. antiserum to bacteria serum 
P = 0.001 (**) (unpaired t-test). 
 These results indicated that the immunogenicity of HdLOS was dependent on both the 
oligosaccharide, which probably requires a correct presentation by lipid A, and an intact lipid A. 
Interestingly, hyper-immunization of mice with boiled H. ducreyi bacteria resulted in an anti-
HdLOS response that was weaker than that induced by purified HdLOS (Fig 11). However, this 
might depend on many factors e.g. the total amount of bacterial LOS injected, the presentation 
of LOS on the bacterial surface, the release of LOS to the environment and an eventual 
conformational exposure in LOS structure etc. 
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2.2. SPECIFICITY OF ANTIBODIES INDUCED BY HDLOS 
To investigate the specificity of the generated HdLOS antibodies an inhibition study was 
performed. Anti-HdLOS sera was adsorb with HdLOS4438, HdLOS7470, lacto-N-neotetraose 
(LNnT), or a 3‟sialyllactose and the majority (97-98%) of antibodies induced by HdLOS7470 
were absorbed by homologous or heterologous HdLOS and only about 15%+ 5% (mean + SD) 
of antibodies were absorbed by LNnT, or the 3‟sialyllactose moiety (unpublished data). In order 
to detect and quantify antibodies with specificity for the non-reducing sialylated end of the 
HdLOS, ELISA plates coated with either sialyl-LNnT or LNnT conjugated to human serum 
albumin (HAS) as antigen was used. Low but significant levels of antibodies specific for lacto-
N-neotetraose moiety in the anti-LOS sera were detected (paper II). For the detection of 
antibodies to the distal epitopes of HdLOS exposed on the bacterial surface, the antibody levels 
in anti-HdLOS7470 sera were estimated using whole cell ELISA. We found that the mean 
antibody titer (n=10) was about 150 times lower than when the sera were tested against purified 
HdLOS (data not shown). When the binding capacity of anti-HdLOS7470 antibodies to selected 
human glycosphingolipids was tested on thin-layer chromatograms, the antibodies bound to 
HdLOS7470, HdLOS4338 and strongly to LipidA-Kdo-Kdo, but no binding of the antibodies to 
any of the glycosphingolipids were detected (paper II). It should though be noted that the 
solvent system used was optimized for the separation of glycosphingolipids, while the resolution 
of the LOS compounds was relatively poor.  
 These results indicated that majority of antibodies generated against HdLOS were specific 
for a fragment common to the LOS of both strains, i.e., the inner core of the LOS and that 
antibodies to the distal part of the HdLOS are not induced in sufficient amounts to bind to the 
related glycosphingolipid tissue structures. In addition, anti-HdLOS antibodies strongly bound 
to the Lipid A-Kdo-Kdo structure. 
2.3. ANTI-INFLAMMATORY ACTIVITY OF ANTI-HDLOS ANTIBODIES 
In the first paper HdLOS was shown to induce production of TNF-α by monocytes derived DCs 
and MQs. With the purpose to exemplify the inflammatory effects caused by HdLOS7470 or 
HdLOS4438 and evaluate anti-inflammatory activities of antibodies specific to HdLOS, the 
TNF-α release from PBMCs was chosen as a parameter to be measured. For comparison was the 
LOS of an E. coli Ra strain (with similar MW) used. Both of the HdLOS preparations, as well as 
the E. coli LOS were found to be potent inducers of TNF-α secretion (Fig 12). The 
concentration of TNF-α secreted by PBMCs was 8 times higher than detected for DCs in paper I 
(Fig 5). This difference in cytokine production can probably be explained by the mixed 
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composition of cells in the PBMC culture. The anti-inflammatory activity of the HdLOS 
specific antibodies were assessed as the inhibition of TNF-α secretion from HdLOS stimulated 
PBMC, but no significantly inhibition of the TNF-α secretion was detected in three out of four 
PBMC preparations, even at the highest concentration of antiserum (Fig 12).  
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Fig 12. Antiserum to HdLOS fails to inhibit TNF-α release from stimulated PBMC. The PBMC 
from one donor were stimulated for 18 h with different amounts of E. coli Ra LOS. HdLOS-
stimulated PMBC were treated with LOS in addition to homologous anti-LOS antiserum (final 
dilution 1:10) or pre-immune serum (control). After 18 h, the supernatants were collected and 
TNF-α was measured by ELISA. The TNF-α levels were calculated relative to the reference 
values, and are expressed in pg/ml (mean + SEM of 3 estimations) with the control values being 
extracted. 
 
2.4. ADJUVANT ACTIVITY OF HDLOS 
The generation of antibodies to HdLOS was found to be dependent on an intact lipid A moiety, 
therefore the possibility of an adjuvant activity of HdLOS was investigated, based on the fact 
that Monophosphoryl Lipid A is a regularly used as adjuvant e.g. in the production of 
monoclonal antibodies in animals. We used BSA as a parameter of the antibody production and 
immunized BALB/c mice with BSA alone or with the addition of 1 μg or 5 μg of HdLOS7470 
(Fig 13A). After three sc immunizations with BSA and HdLOS together were the total IgG 
antibody levels 9-10-fold higher than those observed after immunization with BSA alone. Both 
doses of HdLOS showed adjuvant capacities, with 5 μg of LOS having the most potent activity. 
The predominant IgG subclass raised against BSA was IgG1, followed by IgG2a and an 
approximately 30-fold increase in IgG2b and a 5-fold increase in IgG2a were noted when 
HdLOS was added. 
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 These results indicate that the addition of HdLOS not only increased the antibody 
response to BSA, but also changed the IgG distribution pattern to resemble that obtained by 
immunization of mice with purified HdLOS. 
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Figure 13. Adjuvant activity of HdLOS7470 on antibody responses to BSA in BALB/c mice. 
(A) Total IgG response to BSA. (B) IgG1, IgG2a, IgG2b, and IgG3 subclasses to BSA. BALB/c 
mice (n = 10) were immunized sc three times with 5 µg of BSA with or without the addition of 
1 µg or 5 µg of HdLOS7470 as adjuvant. Ten days after the last injection the induced antibody 
levels were measured by ELISA the levels of total IgG anti-BSA are expressed as units/ml  
(1 units correspond with an end point titer of 1:500). The levels of IgG1, 2a, 2b, and 3 
subclasses were measured by ELISA and the results are expressed as antibody end point titer, 
mean + SEM. BSA vs BSA + 1 µg HdLOS, P = 0.001 (**); for BSA vs.. BSA + 5 µg HdLOS,  
P = 0.0001 (***). 
 
 Question arises, if HdLOS could act as an adjuvant for the stimulation of HdCDT 
antibody production in the same manner as for BSA. The sera were analyzed for HdCDT 
specific antibodies by ELISA and three sc immunizations with HdCDT and HdLOS together 
resulted in a significantly increase in the anti-HdCDT IgG antibody level (P=0.007), 
 as compared with the levels observed after immunization with HdCDT alone (paper III).  
In contrast to the subclass switch reported for the anti-BSA antibodies, the dominating IgG 
subclass in the anti-HdCDT sera were still IgG1 and the addition of LOS only slightly elevated 
the IgG2b response to HdCDT (paper III).  
In summary purified HdLOS significantly increased the antibody responses to BSA and 
HdCDT, thus working as an adjuvant. 
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3. EVALUATION OF HDCDT IMPACT ON THE SERUM ANTIBODY RESPONSES USING A MOUSE 
MODEL (PAPER III) 
3.1. MOUSE MODEL 
As a first step the effect of HdCDT intoxication in different mouse cell lines was investigated in 
order to justify for the use of mouse as a model for our studies of the HdCDT effect on serum 
antibody response. We found that the mouse cell lines tested were sensitive to HdCDT 
intoxication and that the G2 cell cycle arrest was similar as previously reported for both human 
and rabbit cells, though the concentration of toxin needed for intoxication of mouse cells was 
higher. Furthermore the internalization of Alexa Fluor 488 labeled HdCDT in the two different 
epithelial mouse cell lines MLE and m-ICc12 was compared with the epithelial human cell line 
HeLa (paper III). By the use of confocal microscopy the HdCDT internalization pattern was 
visualized and found to be the same in the mouse cell lines and HeLa, provided a higher dose of 
HdCDT in combination with a longer period of incubation with the toxin was used. 
 Taken together, these results indicated that mouse cells involved in immune response are 
sensitive to HdCDT and are intoxicated in a similar manner as human cells, provided a higher 
amount of HdCDT. Therefore we concluded that different impacts of HdCDT on antibody 
responses could be investigated in mice. 
3.2. HDCDT INFLUENCE ON ANTIBODY RESPONSE TO HSP, HDLOS AND BSA 
In order to investigate the effect caused by HdCDT on the antibody response, mice were 
immunized 2-4 times with viable non-toxin producing strain of H. ducreyi 4438 alone or 
together with 10 µg active HdCDT. The serum antibodies to HSP were analyzed by ELISA and 
no significant differences in the antibody response were detected (Fig 14A). 
 The effect caused by HdCDT on the antibody response to purified HdLOS and BSA was 
evaluated as well. Subsequently mice were immunized with purified HdLOS or BSA  
(5 µg/dose) alone or together with active HdCDT (5 µg/dose). The addition of toxin did not 
affect the antibody response to HdLOS (data not shown), but resulted in an enhanced antibody 
response to BSA, with a significant increase in antibody titer (ELISA) after the second 
immunization (P= 0.007) (Fig 14B).  
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3.3. ANTIBODY RESPONSE TO HDCDT 
 When antibody response against HdCDT in sera from mice immunized with H. ducreyi 
4438 together with 10 µg active HdCDT was analyzed, by ELISA. A significant increase of 
anti-HdCDT antibodies was detected in sera after 3 immunizations with bacteria and toxin 
together, giving the end point titer of about 1:2500 (Fig 14C). In the same serum antibodies 
induced to HSP, which is exposed on bacteria the HSP specific antibody titers were 12 times 
higher. However, immunization with 5 μg HdCDT or BSA, a protein with similar molecular 
weight as HdCDT holotoxin, resulted in antibody endpoint titer to HdCDT of 1:800  
(paper III, Fig 3 A) and BSA of 1:50 000 (fig 14), the last about 60 times higher. This result 
indicates that HdCDT is not as immunogenic as the other proteins. 
HdCDT neutralizing antibodies were detected after three immunizations in some of the 
sera and after 4
 
sc. immunizations with bacteria and 10 µg HdCDT neutralizing antibodies were 
detected in all sera, however the levels were low (Fig 14D). In addition no anti-HdCDT 
antibodies were detected in the saponin extract from the genital tissue (not shown) 
 Taken together the active HdCDT was proven to be poorly immunogenic and did not 
significantly impair the serum antibody response to HdLOS or protein. Furthermore at least 
three injections with high 10µg of active HdCDT were needed to generate an anti-HdCDT 
antibody response in serum, though with infrequent naturalizing capacity.  
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Fig 14. Impact of HdCDT on serum antibody response. Balb/c mice immunized sc 2 or 3 times 
with; A) and C), 10
6
 CFU H. ducreyi 4438 (■) or 106 CFU H. ducreyi 4438 + 10µg HdCDT 
(▲), B) 5 µg BSA (■) or 5µg BSA+ 5µg HdCDT (▲). Serum IgG antibodies to A) purified  
H. ducreyi HSP, B) BSA and C) HdCDT. Antibody levels were estimated using ELISA and 
expressed as end point titer, the values represent the mean + SEM (n=5-6). D) HdCDT 
neutralizing antibodies in detected in sera from Balb/c mice immunized sc 2- 4 times with 10
6
 
CFU H. ducreyi 4438 + 10µg HdCDT. A) ns., B) BSA vs. BSA + HdCDT after 2 
immunizations, P=0.007 (**), after 3 immunizations P=0.03 (*) and C) H. ducreyi 4438 vs.  
H. ducreyi 4438 + HdCDT after 3 immunizations, P=0.008 (**). D) H. ducreyi 4438 + HdCDT 
3 vs. 4 immunizations P= 0.04(*), (unpaired t- test).  
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4. GENERATION OF ANTIBODIES TO HDCDT IN THE GENITAL TISSUE USING A MOUSE MODEL 
(PAPER III) 
Even though mice were immunized with 10 µg of active HdCDT in combination with bacteria, 
no HdCDT specific antibodies were detected in the genital tract. In another study we showed 
that formaldehyde treatment of HdCDT increased the immunogenicity and decreased the 
toxicity of the toxin [153]. Therefore formaldehyde detoxified HdCDT was used in an attempt to 
generate toxin antibodies with neutralizing capacity. HdCDT specific antibodies were detected 
in sera and genital tissue after three immunizations, as estimated ELISA. The level of HdCDT 
specific antibodies generated in response to the HdCDT toxoid in sera were about 30 times 
higher than the level of antibodies generated to active HdCDT. The addition of adjuvants 
increased in the generation of anti-HdCDT IgG antibodies in both sera and genital tissue, as 
compared with HdCDT toxoid alone (Fig 15A). In addition, only very low levels of anti-
HdCDT IgA were detected in sera and genital tissue (data not shown).  
The IgG antibody levels in sera and genital tissue, showed high correlation (r=0.8)  
(Fig 15B). 
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Fig 15. A) IgG antibodies to HdCDT in sera and genital tract in Balb/c mice immunized 3 times 
sc with HdCDT toxoid (white bar), HdCDT toxoid + RIBI (black bar) or HdCDT toxoid + Alum 
(hatched bar) estimated by ELISA and expressed as end point titer, bars represent the mean + 
SEM (n=5). B) Correlation between serum anti-HdCDT IgG and vaginal tract anti-HdCDT IgG. 
A) Toxoid vs. toxoid + RIBI, sera P= 0.002(**), genital tract P= 0.02 (*) (unpaired t- test). B) 
Pearson correlation r = 0.8.  
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When the neutralizing capacity of the anti-HdCDT sera was tested, only sera with high 
ELISA titer, about 1:20 000, manifested neutralizing capacity and the correlation between the 
neutralizing capacity of the antibodies and ELISA anti-HdCDT IgG level in the sera was high 
(r=0.7) (Fig 16). This correlation was increased in the sera with the highest antibody levels  
(r= 0.8). 
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Fig 16. Correlation between serum anti-
HdCDT IgG and HdCDT neutralizing titers 
in sera from Balb/c mice immunized 3 times 
sc with HdCDT toxoid, HdCDT toxoid + 
RIBI or HdCDT toxoid + Alum. Serum 
anti-HdCDT IgG were estimated by ELISA 
and expressed as end point titer. 
Neutralizing titer was estimated using toxin 
neutralization assay.  
Pearson correlation r = 0.7. 
 These results indicate that in order to generate antibodies in the genital tissue, parental 
immunization is sufficient, provided the induced antibody levels are high. Furthermore, the 
neutralizing capacity of the antibodies was found to correlate with high levels of anti-HdCDT 
antibodies in sera. 
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GENERAL DISCUSSION 
This thesis evaluates the role of lipooligosaccharide and the cytolethal distending toxin 
produced by Haemophilus ducreyi (HdCDT and HdLOS) in antibody responses. The decision to 
focus on the two toxins, LOS (endotoxin) and CDT was based on the potential importance of 
them in the immunopathogenesis of chancroid. HdLOS is reported to be involved in ulcer 
production in animal models [34-35, 40]. Endotoxin produced by Gram–negative bacteria is an 
important inducer of the inflammatory responses in the early stages of infection and antibodies 
directed against the O-side chain of the polysaccharide may efficiently eliminate bacteria 
through antibody dependent complement-mediated bactericidal activity [76-78, 80]. HdCDT is 
most likely an important factor in the pathogenesis of H. ducreyi. The toxin efficiently kills cells 
involved in the immune response and is reported to contribute to the retardation of healing and 
thereby to the persistence of infection, in vivo [38-39, 124, 126, 136, 138]. To investigate the 
induction of antibody responses against H. ducreyi antigens and to evaluate if a possible 
protective role of antibodies is important for the future development of a vaccine against this 
extracellular bacterium. 
As a first step, the early stage in the immune response to H. ducreyi was evaluated using 
human APCs, in vitro. H. ducreyi and HdLOS induced human monocyte-derived DCs and MQs 
to produce pro-inflammatory cytokines in a similar way as other Gram-negative bacteria  
[157, 165-167]. The production of cytokines by antigen presenting cells is an important factor in 
the differentiation of naïve and uncommitted T-cells into effectors of a Th1- or Th2-type [63]. In 
our study DCs and MQs pulsed with H. ducreyi bacteria and MQs pulsed with HdLOS were 
found to produce e.g. IL-12 and induced CD4
+
 T-cells to produce IFN-γ which is a typical 
marker of a Th1-type immune response. It should be pointed out that in our study only APCs 
derived from monocytes purified form human peripheral blood were employed, while in skin or 
genital mucosa other residential antigen presenting cells may be involved in early responses. 
However, our in vitro results supports the previous finding that the early response to H. ducreyi 
in human experimental infection was of the Th1-type [168]. The Th1-type immune responses in 
infection are dominated by intense phagocytic activity and low antibody production, later it 
switches to a Th2-type immune response which is characterized by high antibody titers and  
re-establishment of homeostasis to protect the host from tissue destruction (reviewed in [63]). 
Antibodies are generally considered to be of great importance in the defence and protection 
against extracellular pathogens and their toxins. H. ducreyi infection is persisting without 
antibiotic treatment, suggesting that bacteria are not easily eliminated by the host defences [7].  
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It was postulated that the Th1-type response might dominate throughout the H. ducreyi infection 
and as mentioned previously humans mount what appears to be a delayed type hypersensitivity 
(DTH) reaction in response to chancroid and experimental H. ducreyi infection [27, 29, 64, 
168]. Anyhow, antibodies against bacterial antigens are produced during infection with  
H. ducreyi and it is of great interest to evaluate the importance of antibodies in the defense 
against H. ducreyi [67-69, 94-95]. 
HdCDT is reported to cause DNA damage and death of DCs and our results confirmed 
this report since HdCDT decreased the viability and slowly induced progressive apoptosis of 
human monocyte-derived DC [125]. In addition, HdCDT is reported to efficiently induce cell 
cycle arrest and apoptosis/necrosis of other cells involved in the immune response [138, 140]. In 
our in vitro studies with human cells high doses of HdCDT resulted in inhibited cytokine 
secretion and inability of APCs to induce T-cell activation. The lack of T-cell proliferation in 
response to HdCDT pre-treated APCs is probably due to the fact that intoxicated DCs undergo 
cell death and only live DCs are able induce T-cell proliferation [169]. However, it should be 
pointed out that the inhibited cytokine secretion and the inability of human APCs to induce  
T-cell activation in vitro was dependent on high doses of HdCDT and the biological relevance 
of these findings needs further evaluation. Thus, HdCDT might influence the antigen-presenting 
capacity of APCs and thereby inhibit the in vivo immune responses to H. ducreyi, provided a 
sufficient amount of toxin is produced during infection, with consequences as prolonged ulcer 
healing and decreased production of antibodies that can protect the host against subsequent 
infections. The toxin effects observed in vitro raise the question of an eventual impact of 
HdCDT on the antibody responses during H. ducreyi infection, studied here in mice  
[27, 29, 64].  
Specific antibodies to H. ducreyi heat shock protein (HSP) and HdLOS were generated in 
mice after subcutaneous immunization with live H. ducreyi bacteria or purified HdLOS, 
respectively. HSP is an dominating protein with extra-cellular localization and are expressed in 
high amounts when H. ducreyi bacteria are grown, in vitro [159]. HdLOS is another surface 
localized antigen and HdLOS antibodies were detected in sera from chancroid patients  
[94-95].  
 In our experimental model as much as 10 µg of active HdCDT protein per dose was used 
to induce an antibody response and still low titers were noted. Immunization of mice with BSA, 
a protein with similar molecular weight as the HdCDT holotoxin induced a 60 fold higher 
antibody level. The different subunits of HdCDT are of low MW, in our toxin preparation they 
are produced separately in different recombinants and reconstituted using GST immobilized 
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CdtB with the addition of CdtA and CdtC [38, 120]. The purified toxin preparation showed two 
low molecular peaks, indicating that the holotoxin with 70 kDa MW is not assembled in solution 
[153]. In previous studies low levels of toxin specific antibodies were detected in sera from 
patients with proven chancroid or experimental H. ducreyi infection in humans  
[69-70, 168, 170-171]. The duration of bacterial persistence in lesions it not known nor is the 
amount of toxin produced during infection known. These factors may influence the antibody 
response to HdCDT. 
In order to evaluate if HdCDT could influence the generation of antibodies, we first proved that 
mouse cells were sensitive to HdCDT intoxication in a similar way as previously reported for 
human and rabbit cells [120, 124, 130, 132, 140, 172]. We considered a mouse model as 
relevant for our HdCDT studies based on the cell results and studies concerning other CDT 
producing bacteria e.g. H. hepaticus and C. jejuni [173-174]. 
We used active HdCDT in a dose of 10μg protein, which was about 100 times the amount 
of toxin causing a 50% decrease in viability of mouse immune cells, in vitro, in order to assure 
that local and distal immune cells could be affected. The decision to use this amount of toxin 
was also based on the report that 10μg was the lowest dose of HdCDT that induce inflammation 
in rabbit skin [38].  
CDT produced by H. ducreyi and other bacteria is suggested to act as an immunotoxin 
(reviewed in [112]). However, our results indicated that the serum antibody responses to 
unrelated protein antigen (BSA) and bacterial proteins were not significantly down-regulated in 
mice by simultaneous injection of HdCDT, despite the fact that a very high concentration of 
toxin was used and T-cells, B-cells and antigen presenting cells are proven to be sensitive to 
active HdCDT in vitro [136, 138]. It is possible that HdCDT is transported to lymph nodes 
already bound to cells from the site of infection and thus unable to influence T-cells and B-cells 
in the lymph nodes and if so the toxin probably only has a local cellular effect in lesions.  
Purified HdLOS possessed adjuvant activity which resulted in a significantly increased antibody 
response to BSA and HdCDT, including a shift of the IgG subclass composition from IgG1 
towards IgG2 for BSA. The immune response to BSA was modulated in a similar way that 
different LOS structures from Neisseria meningitidis serogroup B modulated the response to 
outer membrane proteins [79]. However, in infectious situation this activity may not 
significantly influence the antibody response to other bacterial antigens, including CDT. 
When the biological activity of the antibodies generated against HdLOS was evaluated, they 
were found to be incapable of neutralizing the endotoxic activity generated by HdLOS, as 
measured by TNF-α released by PBMCs. In addition, the complement mediated serum 
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bactericidal activity, which is an important primary host defense against Gram-negative bacteria, 
was not enhanced by the high levels of anti-HdLOS antibodies in mouse sera, in agreement with 
a previous report regarding human and rabbit anti-HdLOS antibodies. In addition, this report 
indicated that the HdLOS antibodies were somehow blocked from LOS accessibility [97]. Our 
studies indicated that LOS, being a T-cell independent antigen was very immunogenic in 
contrast to e.g. Campylobacter jejuni LPS which was of low immunogenicity [175]. The 
antibodies generated were found to be directed against the core of the oligosaccharide and not to 
the distal part. The specificity partly explains the low biological activity of the antibodies, since 
the core region of the LOS is not exposed on the surface of bacteria and thus not accessible for 
antibody binding. The distal part of LOS is reported to be immunochemically identical with 
paragloboside, a glycoshingolipid precursor of human blood antigens and this molecular 
mimicry of host structure by HdLOS is another suggested mechanism for H. ducreyi to evade 
the specific antibody response [86]. In addition, H. ducreyi produces the following virulence 
factors; ducreyi serum resistance A (DsrA), ducreyi lectin A (DltA), and major outer membrane 
proteins (MOMP), which are reported to contribute to serum resistance probably by hiding of 
epitopes [45, 47, 56]. As evidence from above, the biological activity of the HdLOS specific 
antibodies in disease most certainly needs further evaluation. 
 An important aim of this thesis was to generate toxin neutralizing antibodies in the genital 
tract, since those antibodies are of great importance in the defense against sexually transmitted 
pathogens. The presence of IgG antibodies in female genital secretions reflect that of serum, 
suggesting that IgG originates from the circulation. However, reports that genital IgG antibody 
does not always correlate with that of serum imply that at least some IgG originates from local 
sources. Regardless of the source, however, the route of passage into the lumen, whether by 
passive (paracellular) diffusion or through an active transport mechanism is not known [176]. 
Different routes of mucosal antigen delivery and adjuvants for the generation of antibodies 
in the genital tract of mice have been extensively studied [177-180]. The demonstrated induction 
of protective antibodies against human papillomavirus (HPV) was of special interest for us, 
since HPV, similarly to H. ducreyi, acts on the genital skin and mucosal epithelium, and causes 
persistent infection with lesion development as consequence. HPV vaccines based on L1 virus-
like particle (VLP) are reported to prevent genital HPV infection after intramuscular injections 
with aluminum salt. The combination of the adjuvants MLP and aluminum salt was reported to 
be more efficient in the induction of a persistent immune response against HPV16/18 in human 
as compared to aluminum salt alone [181]. Local administration of HPV16 L1 VLPs was 
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dependent on the use of potent adjuvant in order to generate neutralizing antibodies in serum 
and in genital, rectal and oral secretions in mice [180]. 
 In an attempt to induce HdCDT antibodies in the genital tract a toxoid based on 
formaldehyde detoxified HdCDT developed in our laboratory was used in the present 
investigation. The detoxification procedure cross-linked the three protein subunits, resulting in a 
protein complex of 70 kDa produced a very immunogenic toxoid [153]. In this study parenteral 
immunization of mice with HdCDT toxoid alone or in combination with RIBI or aluminum salt 
resulted in the generation of high anti-HdCDT serum antibody levels. The high levels of 
HdCDT specific antibodies in sera correlated with the level of antibodies extracted from genital 
tissue. In addition, only serum with high anti-HdCDT antibody titers possessed toxin 
neutralizing capacity. The antibodies extracted from genital tissue were not tested by 
neutralizing assay, since saponin used in the extraction protocol is toxic to cell cultures [182]. 
But, it is most likely that antibodies with toxin neutralizing capacity in sera can be transferred to 
the genital tract and give raise to neutralizing activity there.  
 Antibodies with toxin neutralizing capacity are of great importance in the host defense 
against bacterial toxins and are protective in several toxin mediated diseases e.g. tetanus, 
diphtheria and whooping cough [183-184]. However, in chancroid patients only low levels of 
toxin neutralizing antibodies are detected in sera and their protective capacity in chancroid is not 
clear [69-70].  
Furthermore, in the case of localized aggressive periodontitis, caused by another CDT 
producing bacterium, A. actinomycetemcomitans, the majority of patients were unable to mount 
a significant anti-AaCDT antibody response, which provided a partial explanation for their 
susceptibility to the disease [152]. The neutralizing antibodies are often specific to epitopes 
situated on the receptor binding subunits of AB toxins [185]. In the case of HdCDT, a 
monoclonal antibody directed against CdtC was reported to possess toxin neutralizing activity 
[69]. In addition, Wising et al. reported that immunization of rabbits with the HdCDT holotoxin 
or the individual protein subunits CdtA, CdtB or CdtC resulted in generation of antibodies with 
neutralizing capacity and the antibodies to the individual subunits exerted lower neutralizing 
capacity than the antibodies generated to the holotoxin [38]. In order to shorten the infection and 
allow epithelialisation, HdCDT neutralizing antibodies are most likely needed at the site of 
bacterial infection. In the case of chancroid HdCDT neutralizing antibodies in the genital region 
should for that reason be of great value. However, the importance of HdCDT neutralizing 
antibodies in a H. ducreyi infection is difficult to evaluate since no model is available for the 
study of persistent infection.  
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Based on these results high level of toxin neutralizing antibodies achieved by parental 
immunization with HdCDT toxoid might be sufficient to exert toxin neutralizing activity in the 
genital tissue and therefore the toxoid is recommended to be tested as a component of a future 
vaccine candidate against H. ducreyi and other CDT producing bacteria.  
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CONCLUSIONS 
1. Interactions of H. ducreyi bacteria and HdLOS with human monocyte-derived DCs and 
MQs stimulated a pro-inflammatory cytokine response. CD4
+
 T-cells responded to bacterial or 
HdLOS activated DCs and MQs with increased proliferation and secretion of INF-γ, but not of 
IL-4 and IL-13, indicating that a Th1-type immune response occurs in the early stages of  
H. ducreyi infection. 
HdCDT decreased the viability and caused progressive apoptosis of the DCs, provided a 
high toxin concentration was used. In addition, HdCDT directly or indirectly inhibited the 
secretion of inflammatory cytokines by DCs and MQs and intoxication subsequently resulted in 
failure of the APCs to activate CD4
+
 T-cells. 
 
2.  Purified HdLOS is an immunogenic T-cell independent antigen, dependent on the TLR4 
signaling pathway for induction of specific HdLOS antibodies in mice. The majority of the anti-
HdLOS antibodies are specific for the inner core of LOS and those antibodies are not 
significantly involved in the neutralization of HdLOS endotoxic activity. Purified HdLOS 
exerted adjuvant properties and significantly increased the antibody responses to proteins tested 
(BSA and HdCDT), and stimulated an increase in antibodies of the IgG2b subclass. 
 
3.  Active HdCDT does not down-regulate the humoral antibody response to H. ducreyi 
antigens, as tested for different proteins and purified lipooligosaccharide.  
 
4.  The active HdCDT is weakly immunogenic and as many as four immunizations with  
10 µg of protein is needed in mice to induce toxin neutralizing antibodies. Parenteral 
immunizations with HdCDT toxoid alone and in combination with aluminum salts or lipid A 
based adjuvants induce high levels of serum and genital HdCDT specific IgG antibodies, 
including neutralizing antibodies.  
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SWEDISH SUMMARY - POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ SVENSKA 
Den här avhandlingen är fokuserad på två toxiner (gift) som bakterien Haemophilus ducreyi 
producerar. H. ducreyi är en gramnegativ bakterie som orsakar den sexuellt överförbara 
könssjukdomen chancroid, vilken kännetecknas av svårläkta sår på de yttre könsorganen. De två 
toxinerna, lipooligosackarid (LOS) och cytoletalt distanserande toxin (CDT) bidrar till bildandet 
av de chancroida såren. Liksom andra könssjukdomar har chancroid visat sig öka 
smittspridningen av HIV och i dagsläget finns det inget vaccin mot sjukdomen utan den botas 
med antibiotika. 
 
Lipopolysackarid (LPS) är en huvudsaklig komponent i gramnegativa bakteriers cellvägg 
och består av en inre fettsyra och en yttre kolhydratkedja. Det LPS som H. ducreyi producerar 
har till skillnad från många andra bakteriers LPS en mycket kort kolhydratkedja och benämns 
därför LOS. CDT är ett protein som består av tre subenheter. Det är sedan tidigare känt att CDT 
skadar cellers DNA, vilket leder till celldöd. Vid en bakteriell infektion kan antikroppar riktade 
mot en särskild komponent, som exempelvis ett toxin, på ett effektivt sätt neutralisera detta. Det 
är ännu inte klarlagt vilken betydelse antikroppar har i försvaret mot chancroid och om dessa två 
toxiner påverkar bildandet av antikroppar under en H. ducreyi infektion. Det huvudsakliga målet 
med arbetet var därför att undersöka hur de båda toxinerna påverkar bildandet av H. ducreyi–
specifika antikroppar.  
 
Vi fann att levande H. ducreyi och framrenat LOS inducerade mänskliga celler 
involverade i vårt immunförsvar att producera inflammatoriska cytokiner, dvs. substanser som 
signalerar till kroppen att den är infekterad. Vi undersökte om det bildades antikroppar mot LOS 
och antikropparnas specificitet, dvs. vilken del av LOS som de kände igen, om de hade någon 
funktion samt om LOS kunde påverkade bildandet av andra antikroppar. Det visade sig att 
mycket antikroppar bildades mot LOS och att de kände igen den inre strukturen på LOS. Tyvärr 
var dessa inte kapabla att inaktivera den skadliga effekten av LOS. Det visade sig att LOS 
fungerade som ett immunostimulerande ämne (adjuvant) som hade förmågan att öka 
antikroppsproduktionen mot andra bakteriella komponenter. 
 
När CDTs förmåga att påverka immunförsvarets antikroppsproduktion undersöktes, 
upptäckte vi att endast mycket lite antikroppar var riktade mot aktivt CDT och att de antikroppar 
som bildades inte var särskilt bra på att neutralisera toxinet. Toxinet orsakade inte en minskning 
av antikroppsproduktionen mot andra komponenter, trots att det kan döda celler inblandade i 
immunförsvaret. För att undersöka om antikroppar mot CDT är av betydelse för skyddet mot  
H. ducreyi definierade vi ett sätt att inducera produktionen av antikroppar mot CDT med 
neutraliserande kapacitet. Genom att behandla aktivt CDT med formaldehyd kopplades de tre 
subenheterna i toxinet samman och toxinet förlorade sin förmåga att döda celler. Möss som 
immuniserades med det förändrade CDT i kombination med ett adjuvant, bildade höga nivåer av 
antikroppar mot CDT med förmågan att neutralisera toxinet. 
 
Vi föreslår att man utvärderar om det går att använda inaktiverat CDT som en komponent 
i ett vaccin mot H. ducreyi och andra CDT producerande bakterier. 
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